Please sign in to follow a disease.
Adenocarcinoma
MONDO:0004970A common cancer characterized by the presence of malignant glandular cells. Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous). Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.
Also known as: adenocarcinoma, adenocarcinoma NOS (morphologic abnormality), adenocarcinoma, malignant, adenocarcinoma, no subtype (morphologic abnormality), adenocarcinomas, ADNOS
6815 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
Showing the 400 most recently updated of 1118 trials in this tab.
-
Ovarian cancer vaccine shows promise in early trial
⭐️ VACCINE ⭐️ CompletedThis early-stage study tested a vaccine called DCP-001 in 17 women with a serious type of ovarian cancer who had already completed standard treatment. The goal was to see if the vaccine is safe and can boost the immune system to recognize and fight cancer cells. Researchers measu…
Phase: PHASE1 • Sponsor: University Medical Center Groningen • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:28 UTC
-
New combo aims to extend life in stomach cancer
Disease control CompletedThis study tests whether a combination of ramucirumab plus FOLFIRI (a standard chemo regimen) works better than ramucirumab plus paclitaxel for people with advanced stomach or gastroesophageal junction cancer that has worsened after one prior chemo treatment. About 429 participan…
Phase: PHASE2, PHASE3 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Triple threat before surgery: could a new combo wipe out stomach cancer cells?
Disease control CompletedThis study tests whether giving a three-part treatment before surgery can improve outcomes for people with locally advanced stomach or gastroesophageal junction cancer. The treatment combines an immunotherapy drug (tislelizumab) with standard chemotherapy and a short course of ra…
Phase: PHASE2 • Sponsor: Jiangsu Cancer Institute & Hospital • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New radiation approach aims to tame prostate cancer with fewer side effects
Disease control CompletedThis study tests a type of radiation called high-dose brachytherapy for men with prostate cancer that hasn't spread. Doctors place tiny radioactive sources directly into the prostate to deliver a strong dose to the tumor while sparing nearby healthy tissue. The goal is to control…
Phase: NA • Sponsor: Stanford University • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Drug that starves tumors shows promise against advanced kidney cancer
Disease control CompletedThis phase II trial tests the drug lenalidomide (CC-5013) in people with advanced or inoperable kidney cancer. Lenalidomide works by cutting off blood flow to tumors, which may stop or slow their growth. The study aims to see how many patients respond to treatment and what side e…
Phase: PHASE2 • Sponsor: The Cleveland Clinic • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Experimental drug hopes to boost chemo against tough pancreatic cancer
Disease control CompletedThis trial investigates whether adding antroquinonol (Hocena) to standard chemotherapy (nab-paclitaxel and gemcitabine) can safely treat people with metastatic pancreatic cancer that has not yet been treated. The study has two phases: first, finding the best dose, and second, che…
Phase: PHASE1, PHASE2 • Sponsor: Golden Biotechnology Corporation • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Experimental cell therapy takes aim at Hard-to-Treat cancers
Disease control CompletedThis early-stage trial tests an experimental cell therapy called IBR854 in people with advanced solid tumors that cannot be surgically removed or have spread. The main goals are to check the treatment's safety and find the right dose. Participants receive the cells by infusion tw…
Phase: PHASE1 • Sponsor: Imbioray (Hangzhou) Biomedicine Co., Ltd. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug duo aims to shrink advanced kidney tumors
Disease control CompletedThis phase 2 trial is testing a new drug called cadonilimab (AK104), either alone or combined with axitinib, as a first treatment for advanced or metastatic kidney cancer. The study includes two parts: one testing different doses of cadonilimab alone in various kidney cancer type…
Phase: PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tests an experimental drug called XmAb24306, given alone or with another cancer drug (atezolizumab), in people with advanced solid tumors that cannot be cured. The main goal is to check the drug's safety and how the body processes it. About 195 participants will take p…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug duo shows promise against tough cancers
Disease control CompletedThis study tested whether two drugs, zanidatamab and evorpacept, are safe and can shrink tumors in people with advanced HER2-expressing cancers. Fifty-two patients with breast or other cancers that had spread or couldn't be removed by surgery took part. The goal was to see how ma…
Phase: PHASE1, PHASE2 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Double-Barreled chemo attack on bile duct cancer shows promise
Disease control CompletedThis study tests a two-pronged chemotherapy approach for people with intrahepatic cholangiocarcinoma (a type of bile duct cancer) that cannot be removed by surgery. Participants receive chemotherapy directly to the liver through a surgically placed pump, plus standard chemotherap…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New pill takes aim at Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tests an experimental tablet called YZJ-5053 in people with advanced solid tumors who have no standard treatment options left. The main goals are to find a safe dose and check for side effects. Researchers will also look at how the drug moves through the bo…
Phase: PHASE1 • Sponsor: Shanghai Haiyan Pharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Promising combo tackles tough cancers in early trial
Disease control CompletedThis early-phase study tested the safety of combining two drugs—pembrolizumab (an immunotherapy) and AMG386 (which targets blood vessel growth)—in 62 people with advanced solid tumors like melanoma, ovarian, renal, or colorectal cancer. The main goals were to find the safest dose…
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Could a cup of green tea keep colon cancer away?
Disease control CompletedThis pilot study tests whether a purified green tea extract called EGCG can help prevent colon cancer from coming back after surgery. 51 patients who had their colon cancer removed took either the extract or a placebo. Researchers are checking for changes in DNA methylation, a ma…
Phase: EARLY_PHASE1 • Sponsor: The University of Texas Health Science Center at San Antonio • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Immunotherapy drug durvalumab may be safe for liver cancer patients with active hepatitis b
Disease control CompletedThis study tests whether the immunotherapy drug durvalumab can be safely given to people with advanced liver cancer who also have an active hepatitis B infection. All participants receive an antiviral drug (entecavir) to control the hepatitis B virus. The main goal is to see if d…
Phase: PHASE2 • Sponsor: National Taiwan University Hospital • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New combo therapy aims to stop liver cancer from coming back
Disease control CompletedThis study tests whether adding a targeted drug (Donafenib) and chemotherapy directly into the liver's blood supply can prevent liver cancer from returning after surgery. It includes adults with a single large tumor (≥5 cm) and microscopic blood vessel invasion, who are at high r…
Phase: PHASE2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for kids with liver cancer: personalized treatment shows promise
Disease control CompletedThis study tests a treatment plan tailored to each child's risk level for a rare liver cancer called hepatoblastoma. About 236 children will receive standard treatments like surgery and chemotherapy, plus the drug temsirolimus for high-risk cases. The goal is to see if this appro…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug naderin may help patients fight infections during cancer and TB therapy
Disease control CompletedThis study tested whether adding Naderin (sodium nucleinate) to standard treatment could reduce complications in 75 patients with cancer, tuberculosis, or hepatitis C. The main group received Naderin plus standard therapy, while the control group received standard therapy alone. …
Phase: PHASE2, PHASE3 • Sponsor: MIPO Clinic • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Immunotherapy-Targeted therapy combo shows promise for advanced liver cancer
Disease control CompletedThis clinical trial is testing a combination of two drugs—an immunotherapy (pembrolizumab/quavonlimab) and a targeted therapy (lenvatinib)—as a first treatment for people with advanced hepatocellular carcinoma, a type of liver cancer that cannot be removed by surgery. The study a…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Immunotherapy duo before liver surgery shows promise against cancer
Disease control CompletedThis trial investigates whether giving two immunotherapy drugs, ipilimumab and nivolumab, before liver surgery can help shrink tumors in people with liver cancer (hepatocellular carcinoma). Participants receive the drugs in the weeks leading up to their planned surgery. The study…
Phase: PHASE1, PHASE2 • Sponsor: Imperial College London • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Stool transplants via stoma show promise for treating Post-Surgery colon inflammation
Disease control CompletedThis study tests whether giving patients their own stool bacteria through a temporary stoma can reduce inflammation in the unused part of the colon, a condition called diversion colitis. Sixty-six people with rectal cancer who have a temporary ileostomy will receive either a dail…
Phase: NA • Sponsor: Yongjian Liao • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Study tests skipping extra treatment for early breast condition
Disease control CompletedThis study looks at whether removing a small, low-grade breast change called DCIS with surgery alone is enough. About 158 people with grade 1 or 2 DCIS are being followed to see if the condition comes back. The goal is to find out if some patients can avoid additional treatments …
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New combo approach for kidney cancer shows promise in early trial
Disease control CompletedThis study tested a two-step treatment for medium-sized kidney tumors (4.1-7 cm). First, doctors blocked the tumor's blood supply, then froze it. The goal was to see if this approach is safe and works well. 25 adults with stage T1b kidney cancer took part. The main focus was on s…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug combo shows promise in liver cancer trial
Disease control CompletedThis phase 2 trial tested whether adding an experimental drug called SRF388 to a standard two-drug regimen (atezolizumab plus bevacizumab) helps people with advanced liver cancer that hasn't been treated before. The study enrolled 30 adults whose cancer could not be surgically re…
Phase: PHASE2 • Sponsor: Coherus Oncology, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug combo shows promise in early cancer trial
Disease control CompletedThis early-stage trial tested a new drug called BGB-15025, alone or with another drug (tislelizumab), in 157 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the best dose. The study is now complete, …
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New cancer drug combo tested in early human trial
Disease control CompletedThis early-phase trial tested an experimental drug called IOS-1002, given alone or with the immunotherapy pembrolizumab, in 47 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. Research…
Phase: PHASE1 • Sponsor: ImmunOs Therapeutics AG • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug cocktail aims to make inoperable abdominal cancers operable
Disease control CompletedThis phase 2 trial tested a combination of two drugs—paclitaxel (given intravenously and directly into the abdomen) and oral nilotinib—in 21 adults with cancers that had spread to the lining of the abdomen and could not be surgically removed. The goal was to see if the treatment …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug duo shows promise for Hard-to-Treat cancers
Disease control CompletedThis phase 2 study tested a combination of two drugs—olaparib and pembrolizumab—in 333 adults with advanced solid tumors that have specific DNA repair problems (HRR mutations or HRD). The goal was to see if the combo could shrink tumors or slow their growth. Participants had alre…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Could a depression drug fight prostate cancer?
Disease control CompletedThis phase 2 trial tested phenelzine sulfate (Nardil), an antidepressant, in 26 men with prostate cancer that returned after initial treatment but hadn't spread. The goal was to see if the drug could lower PSA levels, a marker of cancer activity. Researchers measured how many pat…
Phase: PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Can adding cetuximab to chemotherapy prevent colon cancer return?
Disease control CompletedThis large phase III trial studied whether adding the targeted drug cetuximab to standard chemotherapy after surgery helps prevent cancer from coming back in patients with stage III colon cancer. Over 3,300 patients took part, and the study focused on those with a specific geneti…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug cocktail targets Hard-to-Treat ovarian and endometrial cancers
Disease control CompletedThis early-stage trial tested two drugs—niraparib and copanlisib—in 31 people with recurrent endometrial, ovarian, peritoneal, or fallopian tube cancer. The goal was to find the safest dose and see how well patients tolerated the combination. Both drugs work by blocking enzymes t…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Immunotherapy cocktail shows promise against tough rectal cancers
Disease control CompletedThis study tested whether giving a mix of immunotherapy drugs (tislelizumab and IL-2) plus chemotherapy before surgery could shrink tumors more effectively in people with locally advanced rectal cancer. The trial involved 130 adults whose cancers had not spread but were hard to t…
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo shows promise for tough cancers
Disease control CompletedThis study tested a new drug called CT7001, alone or with other cancer treatments, in 124 people with advanced solid tumors like breast and prostate cancer. The main goal was to check safety and side effects. The drug is taken by mouth and aims to control the disease, not cure it…
Phase: PHASE1, PHASE2 • Sponsor: Carrick Therapeutics Limited • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Liver cancer drug combo shows promise in large trial
Disease control CompletedThis study tested whether adding the chemotherapy drug doxorubicin to the targeted therapy sorafenib helps people with advanced liver cancer live longer. Over 350 patients received either sorafenib alone or sorafenib plus doxorubicin. The main goal was to compare overall survival…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Fish oil supplement tested for muscle loss in liver cancer patients
Disease control CompletedThis completed trial tested whether a daily EPA (an omega-3 fatty acid) supplement could help preserve muscle mass and reduce inflammation in 18 people with advanced liver cancer that could not be surgically removed. Participants took either the EPA supplement or a placebo for 12…
Phase: NA • Sponsor: Instituto de Investigación Sanitaria Aragón • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Kidney cancer drugs fail to prevent recurrence after surgery
Disease control CompletedThis large phase 3 trial tested whether taking sorafenib or sunitinib after kidney cancer surgery could prevent the cancer from coming back. Nearly 2000 patients participated. Unfortunately, neither drug improved disease-free survival compared to a placebo, and they caused side e…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug IBI129 tested in humans for first time against Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental drug called IBI129 in 36 adults with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to find a safe dose and check for side effects. Researchers also looked for any signs that the drug mig…
Phase: PHASE1, PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Experimental drug targets Notch-Activated cancer before surgery
Disease control CompletedThis phase 1 trial tested the drug AL101 in 13 people with a rare salivary gland cancer called adenoid cystic carcinoma that has a specific genetic change (notch activation). Participants received AL101 before their standard surgery to see if it is safe and might help control the…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New cancer drug CFI-402257 enters first human trial
Disease control CompletedThis Phase 1 trial tested an investigational oral drug called CFI-402257 in 52 people with advanced solid tumors, including breast cancer, that had stopped responding to standard treatments. The main goal was to find a safe dose and check how the drug moves through the body. It w…
Phase: PHASE1 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Prostate cancer combo: does adding chemo after surgery keep cancer away?
Disease control CompletedThis study looked at 612 men with prostate cancer that had been removed by surgery. It compared standard treatment (hormone therapy plus radiation) against the same treatment plus the chemotherapy drug docetaxel. The goal was to see if adding chemo helps keep the cancer from comi…
Phase: PHASE2, PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Heated chemo during second surgery shows promise for ovarian cancer
Disease control CompletedThis study looked at whether giving heated chemotherapy directly into the abdomen during a second-look surgery is possible for people with ovarian, fallopian tube, or peritoneal cancer. Ten participants who had already received standard treatment were enrolled. The goal was to se…
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Zapping prostate tumors with extra radiation: a new targeted approach
Disease control CompletedThis study tested whether giving a higher dose of radiation specifically to the visible tumor inside the prostate could improve cancer control in men with localized prostate cancer. Eighty-five men either received a standard radiation plan with an extra boost to the tumor or a co…
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New PET scan hunts down hidden prostate cancer for precision radiation
Disease control CompletedThis study tested a new type of PET/MRI scan that uses a special tracer to find small spots of prostate cancer that standard scans miss. Men with a rising PSA after prostate surgery and radiation received targeted radiation to those spots. The goal was to see if this approach can…
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Robot or scalpel? european trial tests less invasive pancreatic cancer surgery
Disease control CompletedThis trial compares two types of surgery for pancreatic cancer in the body or tail of the pancreas: minimally invasive (laparoscopic or robot-assisted) versus traditional open surgery. The goal is to see if the less invasive approach can remove the tumor just as completely. Adult…
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New immunotherapy cocktail aims to simplify cancer treatment
Disease control CompletedThis study tested a fixed-dose combination of two immunotherapy drugs, tiragolumab and atezolizumab, given together as a single infusion every three weeks. The trial enrolled 64 people with advanced solid tumors that express a protein called PD-L1. The main goal was to check the …
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo takes on advanced cancers in early trial
Disease control CompletedThis early-phase trial tested an experimental drug called KVA12123, given alone or with the immunotherapy Keytruda, in 40 adults with advanced solid tumors (like lung, breast, or colon cancer) that had stopped responding to standard treatments. The main goals were to check safety…
Phase: PHASE1, PHASE2 • Sponsor: Kineta Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Cancer-Killing virus plus immunotherapy shows promise in kidney cancer trial
Disease control CompletedThis study tested a combination of two experimental treatments for people with advanced kidney cancer that cannot be removed by surgery. The first is Pexa-Vec, a modified virus designed to infect and destroy cancer cells while also boosting the immune system. The second is cemipl…
Phase: PHASE1, PHASE2 • Sponsor: SillaJen, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Promising cocktail may shrink pancreatic tumors before surgery
Disease control CompletedThis Phase II trial tested a combination of chemotherapy drugs (FOLFIRINOX) plus the blood pressure drug losartan, followed by proton radiation, in 50 people with locally advanced pancreatic cancer. The goal was to see if this approach could shrink tumors enough to allow complete…
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail targets Hard-to-Treat colorectal cancer
Disease control CompletedThis study tests whether a combination of three drugs—cisplatin, nivolumab, and temozolomide—can shrink tumors in people with advanced colorectal cancer that has not responded to other treatments. The cancer must be a specific type called MMR-proficient. The trial involves 18 par…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take on liver cancer in early trial
Disease control CompletedThis early-phase trial tested a new approach for advanced liver cancer that has not responded to standard treatments. Researchers took participants' own immune cells, modified them in a lab to target a protein called AFP found on cancer cells, and infused them back after a short …
Phase: PHASE1 • Sponsor: Adaptimmune • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested a new drug called RO7496353 combined with an immunotherapy (atezolizumab) and sometimes chemotherapy in 102 people with advanced lung, stomach, or pancreatic cancer. The main goal was to check safety and side effects. Researchers also looked at how t…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail aims to stop liver cancer recurrence after surgery
Disease control CompletedThis study tested whether a combination of two drugs (atezolizumab and bevacizumab) can prevent liver cancer from returning in people who had surgery or ablation to remove their tumor. About 668 participants at high risk of recurrence were randomly assigned to receive the drug co…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Immune cells armed with antibody take on pancreatic cancer
Disease control CompletedThis trial tested a new treatment called EGFR BATs for people with advanced pancreatic cancer. The treatment uses a patient's own immune cells, armed with a special antibody, to target cancer cells. The study included 22 participants who had already received chemotherapy. The goa…
Phase: PHASE1, PHASE2 • Sponsor: University of Virginia • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Real-World data shows promise for kidney cancer drug combo
Disease control CompletedThis completed study looked at how well avelumab (BAVENCIO) plus axitinib (INLYTA) works for advanced kidney cancer in everyday medical practice. Researchers tracked 105 patients across multiple EU countries to see survival rates at 12 and 24 months. The goal was to understand th…
Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug shows promise in helping immune system fight advanced cancers
Disease control CompletedThis study tested a drug called PF-06801591 in 155 people with advanced solid tumors or non-small-cell lung cancer. The drug works by blocking a protein that stops the immune system from attacking cancer cells. The goal was to check safety, how the drug moves through the body, an…
Phase: PHASE1, PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Modified virus injected into tumors shows promise for liver cancer
Disease control CompletedThis phase 2 trial tested a modified virus called JX-594 (Pexa-Vec) in 30 people with liver cancer that could not be surgically removed. The virus was injected directly into the liver tumors to see if it could stop the cancer from growing. Researchers measured how many patients h…
Phase: PHASE2 • Sponsor: Jennerex Biotherapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Radiation and immunotherapy combo shows promise in small cancer study
Disease control CompletedThis pilot study tested whether combining high-dose radiation therapy with the immunotherapy drug pembrolizumab (Keytruda) could boost the immune system's ability to fight advanced solid tumors. Twenty-one patients with various advanced cancers received the combination either at …
Phase: PHASE1 • Sponsor: James Larner, MD • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Triple threat: new combo shows promise against tough breast cancer
Disease control CompletedThis phase II trial tested a combination of two targeted antibodies (pertuzumab and trastuzumab) plus a chemotherapy drug (nab-paclitaxel) in 63 patients with HER2-positive advanced breast cancer. The goal was to see how well the drugs work together to stop tumor growth and impro…
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for liver cancer patients with cirrhosis? tiny trial tests drug duo
Disease control CompletedThis small, completed phase II study tested the safety of combining two drugs—atezolizumab (an immunotherapy) and bevacizumab (a blood vessel blocker)—in 6 people with advanced liver cancer who also had moderate cirrhosis (Child-Pugh B7 or B8). The goal was to see if this treatme…
Phase: PHASE2 • Sponsor: Howard S Hochster • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo takes on tough cancers in early trial
Disease control CompletedThis early-phase trial tested a new drug called vilastobart, alone or with another drug (atezolizumab), in 125 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. Researchers also looke…
Phase: PHASE1, PHASE2 • Sponsor: Xilio Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo approach before surgery may improve outcomes for massive liver tumors
Disease control CompletedThis study looked at 715 patients with very large liver cancers (over 10 cm) to see if giving a combination of local treatments (like chemo directly into the liver) and body-wide treatments (targeted drugs and immunotherapy) before surgery helps them live longer. Patients were di…
Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
Drug combo shows promise in Hard-to-Treat cancers
Disease control CompletedThis phase 1 trial tested the combination of dasatinib (a pill) and bevacizumab (an infusion) in 50 adults with advanced solid tumors that no longer respond to standard treatments. The goal was to find the safest dose and see how well the two drugs work together to slow cancer gr…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug duo shows promise for tough cancers
Disease control CompletedThis study tested two experimental drugs (AK104 and AK117) together, sometimes with chemotherapy, in 128 people with advanced solid tumors. The goal was to see if the combination is safe and can shrink tumors. It focused on patients with stomach, esophageal, or other advanced can…
Phase: PHASE1, PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug combo aims to outperform chemo in Tough-to-Treat stomach cancer
Disease control CompletedThis phase 3 trial tested whether a combination of two drugs, regorafenib and nivolumab, helps people with advanced gastro-oesophageal cancer live longer than standard chemotherapy. The study included 462 adults whose cancer had stopped responding to prior treatments. The goal wa…
Phase: PHASE3 • Sponsor: Australasian Gastro-Intestinal Trials Group • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New stomach cancer surgery technique shows promise in early trial
Disease control CompletedThis study tested a new way to reconnect the stomach and small intestine after removing the lower part of the stomach in people with advanced stomach cancer. The goal was to see if the new stapling method was safe and worked well. One hundred patients took part, and the researche…
Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New immunotherapy combo takes on tough pancreatic cancer
Disease control CompletedThis phase 2 trial tested whether adding an immunotherapy drug called botensilimab to standard chemotherapy could help people with metastatic pancreatic cancer who had already progressed on a common chemo regimen (FOLFIRINOX). The study enrolled 81 participants and compared the c…
Phase: PHASE2 • Sponsor: Agenus Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Immune cell combo shows promise in tough head and neck cancers
Disease control CompletedThis early-phase trial tested a new approach for people with advanced head and neck cancer that has come back or spread. It combined specially trained natural killer (NK) immune cells with drugs that help the immune system attack cancer. The study enrolled 11 participants to chec…
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Triple immunotherapy cocktail tested in advanced cancers
Disease control CompletedThis early-phase study tested an experimental drug called APX005M added to two standard immunotherapies (nivolumab and ipilimumab) in 26 people with advanced melanoma or kidney cancer who had not received prior immune therapy. The main goals were to check safety and find the best…
Phase: PHASE1 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New cocktail of three drugs tested for tough bladder cancers
Disease control CompletedThis early-phase trial tested a combination of two chemotherapy drugs (gemcitabine and carboplatin) plus lenalidomide, a drug that blocks blood vessel growth in tumors, in 18 adults with advanced solid tumors, especially urothelial (bladder) cancer. The main goal was to find the …
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Promising drug cocktail targets Hard-to-Treat liver cancer
Disease control CompletedThis study tested a combination of two drugs, cadonilimab and regorafenib, in 36 adults with advanced liver cancer that had worsened after standard treatments. The goal was to see if the combo could slow cancer growth and how safe it was. Results may help develop better options f…
Phase: PHASE1, PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New pill shows promise in shrinking Hard-to-Treat breast tumors
Disease control CompletedThis study tested a new oral drug called BGB-43395 in 33 Chinese patients with advanced or metastatic HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. The goal was to find a safe dose and see if it can shrink tumors wh…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Can Breast-Conserving surgery spare women with multiple tumors from mastectomy?
Disease control CompletedThis trial studies whether breast-conserving surgery (lumpectomy) followed by radiation is a safe and effective option for women aged 40 and older who have two or more breast cancer tumors in the same breast. The goal is to see if this less invasive approach can control the cance…
Phase: PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Virus therapy takes on liver cancer in major trial
Disease control CompletedThis study tested whether adding a virus-based immunotherapy (Pexa-Vec) to the standard drug sorafenib helps people with advanced liver cancer live longer. About 459 adults with advanced liver cancer who had not received prior treatment took part. The approach uses a modified vir…
Phase: PHASE3 • Sponsor: SillaJen, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Tailored immunotherapy cocktail shows promise for tough stomach cancer
Disease control CompletedThis phase 2 trial tested personalized immunotherapy combinations for advanced gastric cancer that had worsened after initial chemotherapy. Researchers matched treatments to tumor genetics: patients with certain genetic features received atezolizumab plus ipatasertib, while other…
Phase: PHASE2 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control CompletedThis early-phase study tested a new drug called BGB-C354, alone or with an immunotherapy (tislelizumab), in 63 people with advanced solid tumors that had not responded to standard treatments. The main goals were to check safety and find the right dose. Researchers also looked for…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New shot form of cancer drug tested in 142 patients
Disease control CompletedThis study tested a new under-the-skin shot version of the cancer drug pembrolizumab (Keytruda) in 142 people with advanced solid tumors. The goal was to see how well the body absorbs the drug compared to the standard IV infusion. Researchers also checked for side effects and how…
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug MK-1200 tested in advanced cancer patients
Disease control CompletedThis study tested a new drug called MK-1200 in 13 people with advanced solid tumors, including stomach, esophageal, bile duct, and pancreatic cancers. The goal was to find safe doses and see if the drug could shrink tumors. The study is complete, but results are not yet available…
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New combo attack on stomach cancer shows promise in small trial
Disease control CompletedThis phase 2 trial tested a combination of radiation, a targeted drug (olaparib), and an immunotherapy (pembrolizumab) in 9 people with advanced stomach or gastroesophageal junction cancer that had spread. The goal was to see if this approach could shrink tumors that were not dir…
Phase: PHASE2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Could a flavonoid combo reverse liver scarring and prevent cancer in hepatitis b?
Disease control CompletedThis completed phase 4 trial tested whether adding SB Flavon (a blend of flavonoids, vitamin C, and L-arginine) to standard Tenofovir therapy can reverse advanced liver scarring (cirrhosis) and prevent liver cancer in 134 people with chronic hepatitis B. The study measured liver …
Phase: PHASE4 • Sponsor: Trieu, Nguyen Thi, M.D. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Experimental drug TdCyd aims to reactivate Tumor-Fighting genes in advanced cancer
Disease control CompletedThis early-phase trial tested a new drug called TdCyd in 27 adults with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to turn back on genes that may slow tumor growth. The main goal was to find a safe dose and check for side effect…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug cocktail shows promise for tough stomach cancers
Disease control CompletedThis phase 2 study tested a combination of two drugs, pembrolizumab and ramucirumab, in 26 people with advanced stomach or gastroesophageal junction cancer that had spread. The goal was to see if the combo could shrink tumors or slow the disease. Participants received both drugs …
Phase: PHASE2 • Sponsor: Samsung Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug combo shows promise in shrinking liver tumors before surgery
Disease control CompletedThis study tested a combination of two drugs (atezolizumab and bevacizumab) given before surgery to people with liver cancer. The goal was to see how well the drugs shrink the tumor and how they affect the immune system. 40 participants were enrolled, and researchers also studied…
Phase: PHASE2 • Sponsor: Tae Won Kim • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Cancer drug safety checked in Long-Term study
Disease control CompletedThis study looked at the long-term safety of several cancer drugs, including tislelizumab and pamiparib, in 404 people with advanced cancers. Participants had already been in an earlier trial of these drugs. The goal was to track serious side effects and see if patients could kee…
Phase: PHASE3 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Targeted drug boosts esophageal cancer treatment in major trial
Disease control CompletedThis phase III trial tested whether adding trastuzumab (Herceptin) to standard chemotherapy and radiation helps people with HER2-positive esophageal cancer. 203 patients were randomly assigned to get chemo and radiation with or without trastuzumab. The study measured how long pat…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Immunotherapy combo shows promise for tough pituitary tumors
Disease control CompletedThis phase 2 trial tested two immunotherapy drugs, nivolumab and ipilimumab, in 10 patients with aggressive pituitary tumors that worsened after surgery and radiation. The goal was to see if the combination could shrink tumors or slow their growth. Researchers also monitored side…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug cocktail shows promise for tough bile duct cancer
Disease control CompletedThis trial tested a three-drug combination—chemotherapy infused into the liver, an immunotherapy drug (tislelizumab), and a targeted pill (regorafenib)—as a first treatment for 31 people with advanced bile duct cancer that couldn't be removed by surgery. The goal was to see how m…
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Zhengzhou University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Blood tests may help decide best time to switch lung cancer drugs
Disease control CompletedThis phase 2 trial tested two drugs, osimertinib and gefitinib, in 156 people with advanced EGFR-mutant lung cancer. The goal was to see if using blood tests (liquid biopsies) to detect genetic changes could help decide when to switch treatments, compared to standard scans. The s…
Phase: PHASE2 • Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo for liver cancer passes safety check in 1,200 patients
Disease control CompletedThis study looked at the safety of two drugs, IMJUDO and IMFINZI, given together or alone to 1,200 people with advanced liver cancer that cannot be removed by surgery. The main goal was to track any side effects that happen in everyday medical use. The study is now complete and h…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Antibody therapy aims to keep colon cancer from returning
Disease control CompletedThis phase III trial tested whether adding a monoclonal antibody called edrecolomab to surgery helps people with stage II colon cancer live longer or stay cancer-free longer. About 2,100 participants were randomly assigned to receive either the antibody or no additional treatment…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Real-World data shows promise for kidney cancer drug combo
Disease control CompletedThis study observed 311 adults with advanced kidney cancer who received cabozantinib (a targeted therapy) plus nivolumab (an immunotherapy) as their first treatment. Researchers tracked how long patients lived and how long tumors stayed under control in real-world settings. The g…
Sponsor: Ipsen • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Engineered immune cells join forces with drugs to fight tough cancers
Disease control CompletedThis phase II trial tested a combination of three treatments: specially engineered natural killer cells (PD-L1 CAR-NK cells), an immunotherapy drug (pembrolizumab), and an immune booster (N-803) in 18 adults with advanced gastric or head and neck cancer that had not responded to …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Major trial tests if abdominal chemo beats IV for tough cancers
Disease control CompletedThis large Phase III trial tested whether adding the drug bevacizumab to chemotherapy works better when the chemo is given into a vein (IV) or directly into the belly (IP). It involved 1560 people with advanced ovarian, fallopian tube, or peritoneal cancers. The goal was to see w…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug XTX202 tested in patients with advanced cancers
Disease control CompletedThis study tested a new drug called XTX202 in 95 people with advanced solid tumors that had not responded to standard treatments. The goal was to check safety, find the right dose, and see if the drug could shrink tumors. The trial is now complete.
Phase: PHASE1, PHASE2 • Sponsor: Xilio Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug given during breast cancer surgery shows early promise
Disease control CompletedThis early-phase trial tested a new drug called SRG-514 in 25 people undergoing breast-conserving surgery for breast cancer. The drug was given directly into the area where the tumor was removed. The main goal was to find a safe dose and check for side effects. This is a first st…
Phase: PHASE1 • Sponsor: SURGE Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug cocktail shows promise against tough pancreatic cancer
Disease control CompletedThis completed phase 1/2 trial tested an experimental drug called Y101D combined with standard chemotherapy (gemcitabine and nab-paclitaxel) as a first treatment for 71 people with advanced pancreatic cancer. The goal was to find a safe dose and see if the combo helps shrink tumo…
Phase: PHASE1, PHASE2 • Sponsor: Wuhan YZY Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Herbal hope: new combo therapy targets advanced pancreatic cancer
Disease control CompletedThis study tested whether adding a Chinese herbal formula (QingyiHuaji) to standard chemotherapy helps people with stage IV pancreatic cancer live longer. About 305 adults with advanced pancreatic cancer were randomly assigned to receive either the herbal formula plus chemo or a …
Phase: PHASE3 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New targeted combo shows promise for tough stomach cancer
Disease control CompletedThis phase 3 trial tested whether adding a targeted drug called bemarituzumab to standard chemotherapy helps people with advanced stomach or gastroesophageal junction cancer that has a specific protein (FGFR2b). The study enrolled 547 adults whose cancer could not be removed by s…
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Could a few weeks of radiation be enough for recurrent prostate cancer?
Disease control CompletedThis early-phase trial tested a shorter course of radiation for men whose prostate cancer came back after their prostate was removed. Instead of the usual 6-7 weeks of daily radiation, researchers gave higher doses over just 2-4 weeks, focusing the strongest radiation on the tumo…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug cocktail aims to tackle childhood cancers that Won't quit
Disease control CompletedThis early-phase study tested a combination of two drugs, cabozantinib and 13-cis-retinoic acid, in 15 children whose solid tumors had come back or were not responding to standard treatments. The main goal was to find the safest dose and understand side effects. The study did not…
Phase: PHASE1 • Sponsor: Peter Zage • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Immunotherapy duo shows promise in kidney cancer battle
Disease control CompletedThis phase 3 trial compared a combination of two immunotherapy drugs (nivolumab and ipilimumab) against the standard drug sunitinib in over 1,000 people with untreated advanced or metastatic kidney cancer. The study measured how well the tumors shrank, how long patients lived wit…
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New radiation schedule may cut treatment time for prostate cancer patients
Disease control CompletedThis phase II trial tested a shorter course of higher-dose radiation (hypofractionation) in 53 men with high-risk prostate cancer who had already had their prostate removed. The goal was to see if this approach could control cancer while reducing side effects. Participants also r…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug combo tested for tough cancers
Disease control CompletedThis early-stage trial tested a new drug called AZD6244 combined with standard chemotherapies in 140 people with advanced solid tumors (breast, colon, lung, melanoma, kidney). The main goal was to see if the combination is safe and tolerable, and to find the best dose. Researcher…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New combo therapy aims to outperform standard care in tough colorectal cancer
Disease control CompletedThis Phase 3 trial tested a new drug combination called MK-4280A (favezelimab plus pembrolizumab) against standard treatments (regorafenib or TAS-102) in 441 people with advanced colorectal cancer that had stopped responding to prior therapy. The goal was to see if the new combin…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug cocktail may make inoperable liver cancer removable
Disease control CompletedThis study tested a combination of chemotherapy infused into the liver artery plus two drugs (camrelizumab and apatinib) in 21 people with liver cancer that could not be surgically removed. The goal was to shrink the tumors enough to allow surgery. The study is complete, and resu…
Phase: PHASE2 • Sponsor: Shandong Cancer Hospital and Institute • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Could a diabetes drug boost lung cancer treatment?
Disease control CompletedThis study looked at whether adding metformin (a common diabetes medicine) to standard chemotherapy and radiation helps people with stage III non-small cell lung cancer live longer without their cancer getting worse. About 170 adults with advanced lung cancer took part. The goal …
Phase: PHASE2 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug combo shows promise for tough stomach cancers
Disease control CompletedThis study tested a new drug called gentuximab combined with the chemotherapy drug paclitaxel in 76 people with advanced stomach or gastroesophageal junction cancer that had worsened after initial treatment. The goal was to find a safe and effective dose and see if the combinatio…
Phase: PHASE1, PHASE2 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Experimental combo targets Hard-to-Treat GI cancers
Disease control CompletedThis early-phase trial tested two drugs together—pembrolizumab (Keytruda) and XL888—in 47 people with advanced gastrointestinal cancers like colorectal and pancreatic cancer that had spread or could not be removed. The main goal was to find the safest dose and check for side effe…
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New kidney cancer drug shows promise in early trial
Disease control CompletedThis early-stage trial tested a drug called belzutifan in 29 people with advanced clear cell kidney cancer that had worsened after other treatments. The main goal was to check safety and find the right dose. Participants took belzutifan pills daily, and researchers monitored side…
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Freezing prostate tumors shows promise in 354-Patient study
Disease control CompletedThis study followed 354 men with low- to intermediate-risk prostate cancer who chose to freeze only the cancerous half of their prostate (hemi-gland cryoablation). Researchers tracked how well the treatment controlled the cancer and how it affected urinary function and quality of…
Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug duo takes on kidney cancer in major trial
Disease control CompletedThis Phase 3 trial tested whether combining pembrolizumab (an immunotherapy) with epacadostat (a drug that boosts the immune response) works better than standard drugs (sunitinib or pazopanib) for people with advanced kidney cancer that hasn't been treated before. The study enrol…
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New antibody combo takes on advanced cancers in first human trial
Disease control CompletedThis early-stage trial tested an experimental drug called LVGN6051, which activates immune cells by targeting CD137, both alone and combined with the approved immunotherapy Keytruda. The study involved 105 adults with advanced or metastatic cancers that had spread. The main goal …
Phase: PHASE1 • Sponsor: Lyvgen Biopharma Holdings Limited • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New hope for tough pancreatic cancer? drug combo trial shows promise
Disease control CompletedThis study tested a new drug called NIS793 added to standard chemotherapy for people with metastatic pancreatic cancer that has spread. The goal was to see if the combination could help patients live longer by reducing scar tissue in the tumor. About 511 adults with this advanced…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Could a PARP inhibitor boost chemo for pancreatic cancer?
Disease control CompletedThis phase 2 trial tested whether adding the drug veliparib to standard chemotherapy (FOLFIRI) helps people with metastatic pancreatic cancer live longer. 123 patients whose cancer had returned after initial treatment were randomly assigned to get FOLFIRI alone or FOLFIRI plus ve…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Experimental vaccine trains immune system to attack kidney tumors
Disease control CompletedThis study tested a personalized vaccine made from a patient's own tumor cells fused with immune cells (dendritic cells) to treat stage IV kidney cancer. The vaccine was given with a drug called GM-CSF to boost immune response. The main goal was to check safety and side effects i…
Phase: PHASE1, PHASE2 • Sponsor: Beth Israel Deaconess Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Shorter radiation after prostate surgery may be just as good
Disease control CompletedThis study tested whether a shorter course of higher-dose radiation (hypofractionated) works as well as standard radiation after prostate removal in 296 men with prostate cancer. The main focus was on quality of life, especially urinary and bowel function. The goal is to find a t…
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New X-Ray tracking could sharpen prostate cancer radiation
Disease control CompletedThis study tested a new X-ray monitoring technique (KIM) during prostate cancer radiation therapy. The goal was to see if it helps doctors aim more precisely at the tumor while reducing harm to healthy tissue. 49 men with low- or intermediate-risk prostate cancer took part. The a…
Phase: NA • Sponsor: University of Sydney • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug combo aims to stop high-risk prostate cancer in its tracks
Disease control CompletedThis study tested whether adding the drug niraparib to standard radiation and hormone therapy can help prevent high-risk prostate cancer from coming back. Niraparib blocks a protein that cancer cells use to repair their DNA, which may kill them. The trial enrolled 22 men with agg…
Phase: PHASE1, PHASE2 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Immunotherapy cocktail before surgery shows promise against tough cancers
Disease control CompletedThis study tested whether adding an experimental drug (CCR2/5-inhibitor or anti-IL-8) to the immunotherapy nivolumab before and after surgery could help shrink tumors and improve long-term survival in people with non-small cell lung cancer or liver cancer. 48 participants receive…
Phase: PHASE2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New antibody combo tackles Hard-to-Treat cancers in early trial
Disease control CompletedThis early-stage study tested a new drug called LVGN7409, which boosts the immune system to fight cancer. It was given alone or with other immune-boosting drugs to 66 adults with advanced cancers that had stopped responding to standard treatments. The main goal was to find the sa…
Phase: PHASE1 • Sponsor: Lyvgen Biopharma Holdings Limited • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug combo shows promise in early pancreatic cancer trial
Disease control CompletedThis early-phase trial tested whether adding a new drug called NP137 to standard chemotherapy (mFOLFIRINOX) is safe and could help shrink tumors in people with locally advanced pancreatic cancer that cannot be removed by surgery. 43 participants received the combination. The main…
Phase: PHASE1 • Sponsor: University Hospital, Grenoble • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Virus injection targets liver tumors in early trial
Disease control CompletedThis early-phase study tested a new treatment called JX-594, a modified virus injected directly into liver tumors. The goal was to find the safest dose and see if it could shrink tumors in 14 patients with advanced liver cancer that had not responded to standard treatments. The s…
Phase: PHASE1 • Sponsor: Jennerex Biotherapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Prostate cancer radiation cut to just 5 sessions in new trial
Disease control CompletedThis phase I trial tested a new type of radiation therapy for low- and intermediate-risk prostate cancer that delivers a higher dose each day, completing treatment in just 5 sessions over 2 weeks instead of the usual 45-48. The study enrolled 120 participants to check the safety …
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New combo therapy targets Hard-to-Treat esophageal cancer
Disease control CompletedThis phase 2 trial tested a two-step treatment for advanced esophageal cancer that has a specific genetic marker (MGMT deficiency) and has stopped responding to standard chemotherapy. First, patients took a daily oral chemotherapy drug (temozolomide) for three months. Then, they …
Phase: PHASE2 • Sponsor: University of Southampton • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New combo therapy shows promise for Tough-to-Treat stomach cancer
Disease control CompletedThis pilot study tested a combination of chemotherapy drugs (FOLFIRINOX plus paclitaxel and carboplatin) along with proton beam radiation before surgery in 25 people with gastroesophageal cancer. The goal was to see if this intense pre-surgery treatment could shrink tumors and be…
Phase: PHASE1 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New cocktail of four chemo drugs shows promise for tough pancreatic cancer
Disease control CompletedThis phase 2 trial tested a combination of four chemotherapy drugs—irinotecan liposome, oxaliplatin, 5-fluorouracil, and levoleucovorin—in 41 Japanese adults with metastatic pancreatic cancer who had not received prior treatment. The goal was to see how well the drugs shrank tumo…
Phase: PHASE2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Promising combo therapy for incurable liver cancer shows potential in phase 3 trial
Disease control CompletedThis study tested whether adding two drugs (lenvatinib and pembrolizumab) to a standard liver cancer treatment called TACE helps people with liver cancer that cannot be removed by surgery. About 479 participants received either the drug combo plus TACE or TACE alone. The goal was…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New registry maps how targeted liver treatment is used in colorectal cancer
Disease control CompletedThis registry followed 152 patients with colorectal cancer that had spread mainly to the liver. Doctors used tiny beads called LifePearl Microspheres loaded with the chemotherapy drug irinotecan, delivered directly to the liver's blood supply. The goal was to see how and when thi…
Sponsor: Cardiovascular and Interventional Radiological Society of Europe • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Drain or no drain? landmark trial settles debate after rectal cancer surgery
Disease control CompletedThis study tested whether placing a temporary drain in the pelvis after rectal cancer surgery reduces the risk of serious infections like leaks or abscesses. About 500 patients were randomly assigned to receive a drain or not. The main goal was to see if drainage lowered pelvic s…
Phase: PHASE3 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Experimental cancer drug NEV801 enters first human tests
Disease control CompletedThis early-phase trial tested an experimental drug called NEV801 in 78 adults with advanced solid tumors that had stopped responding to standard treatments. The drug was given by IV in increasing doses to find the safest dose and to see if it had any anti-cancer effects. The stud…
Phase: PHASE1 • Sponsor: Neovia Oncology Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New combo therapy shows promise in controlling advanced liver cancer
Disease control CompletedThis study tested a combination of Y90 radioembolization (a targeted radiation treatment for the liver) and nivolumab (an immunotherapy drug) in 40 Asian patients with advanced liver cancer that could not be surgically removed. The goal was to see if the combination could shrink …
Phase: PHASE2 • Sponsor: National Cancer Centre, Singapore • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug duo aims to tackle Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug called TJ004309, either alone or combined with another drug called Toripalimab, in 225 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and see early signs of effectiveness. The…
Phase: PHASE1, PHASE2 • Sponsor: TJ Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New hope for pancreatic cancer? drug combo trial shows promise
Disease control CompletedThis study tested whether adding two experimental drugs (TTX-030 and budigalimab) to standard chemotherapy could help people with metastatic pancreatic cancer live longer without their disease getting worse. 194 adults who had not yet received treatment for their advanced cancer …
Phase: PHASE2 • Sponsor: Trishula Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New cancer drug LBL-033 tested in 26 patients – safety first
Disease control CompletedThis study tested a new drug called LBL-033 in 26 adults with advanced malignant tumors that had not responded to other treatments. The main goals were to find a safe dose and check for serious side effects. Researchers also looked at how the drug moves through the body and wheth…
Phase: PHASE1, PHASE2 • Sponsor: Nanjing Leads Biolabs Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New combo therapy shows promise for tough prostate cancers
Disease control CompletedThis study tested a new drug (BXCL701) combined with an immunotherapy (pembrolizumab) in 98 men with advanced prostate cancer that no longer responds to hormone therapy. The goal was to see if the combination could shrink tumors or slow the disease. This is a disease control appr…
Phase: PHASE1, PHASE2 • Sponsor: BioXcel Therapeutics Inc • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug cocktail aims to fight advanced cancers
Disease control CompletedThis early-phase study tested a daily combination of two oral drugs, axitinib and everolimus, in 19 people with advanced solid tumors, particularly kidney cancer. The main goal was to find the safest dose by monitoring side effects in the first month. Researchers also tracked how…
Phase: PHASE1 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New hope for rectal cancer: extra chemo may save the rectum
Disease control CompletedThis phase 3 trial tested whether adding two months of Folfirinox chemotherapy before standard radiation and chemo could help more patients with early-stage rectal cancer avoid major surgery. 218 adults with small, low-lying tumors were enrolled. The goal was to see if more patie…
Phase: PHASE3 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New hope for advanced thyroid cancer: drug shows tumor-shrinking promise
Disease control CompletedThis study tested the drug sunitinib (Sutent) in 71 people with advanced thyroid cancer that had spread or could not be removed by surgery. The goal was to see if the drug could shrink tumors when standard treatments like radioactive iodine no longer work. Participants took sunit…
Phase: PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested a new oral drug called HMPL-453 tartrate, either alone or combined with chemotherapy or an immunotherapy (toripalimab), in 190 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and see if th…
Phase: PHASE1, PHASE2 • Sponsor: Hutchison Medipharma Limited • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Targeted drug shows promise for hard-to-treat stomach cancers
Disease control CompletedThis study tested a drug called savolitinib in 110 people with advanced stomach or esophagus-stomach junction cancer whose tumors have a specific genetic change (MET gene amplification). The goal was to see if the drug could shrink tumors and how safe it was. Participants receive…
Phase: PHASE2 • Sponsor: Hutchison Medipharma Limited • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-stage study tested two drugs, cabozantinib and pamiparib, together in 44 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and understand side effects. The drugs work by blocking certain enzymes t…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug shows promise in early trial for advanced cancers
Disease control CompletedThis early-phase study tested a new drug called CCT3833 in 31 adults with advanced solid tumours, including melanoma. The main goal was to find a safe dose and check for side effects. Researchers measured how the drug moves through the body and looked for the best dose to use in …
Phase: PHASE1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New cancer drug PM14 enters human testing for advanced tumors
Disease control CompletedThis early-phase trial tested a new drug called PM14 in 126 people with advanced solid tumors that had no standard cure. The main goals were to find a safe dose and check for early signs of tumor shrinkage. The drug was given by IV infusion on different schedules. This is a first…
Phase: PHASE1 • Sponsor: PharmaMar • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New combo therapy shows promise in Hard-to-Treat pancreatic cancer
Disease control CompletedThis study tested a combination of three drugs (nivolumab, BMS-813160, and GVAX) in 22 people with locally advanced pancreatic cancer who had already received chemotherapy and radiation. The goal was to see if the treatment was safe and could help the immune system better attack …
Phase: PHASE1, PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Experimental COM902 drug shows promise in early cancer trial
Disease control CompletedThis early-phase study tested an experimental drug called COM902, alone or with other drugs, in 94 people with advanced cancers like ovarian, lung, and colon cancer. The main goal was to check safety and find the right dose. Researchers also looked for early signs that the drug m…
Phase: PHASE1 • Sponsor: Compugen Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New radiation approach shows promise for prostate cancer control
Disease control CompletedThis study tested a new way to give radiation therapy for prostate cancer. It used very precise, high-dose radiation over just five days. The goal was to control the cancer while reducing side effects on the bladder and bowel. 444 men with localized prostate cancer took part, and…
Phase: NA • Sponsor: Fundacao Champalimaud • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Could a triple therapy beat back tough liver cancer?
Disease control CompletedThis completed study tested whether adding a liver-directed chemotherapy infusion (HAIC) to standard immunotherapy and anti-angiogenesis drugs improves outcomes for people with advanced liver cancer that has spread into the portal vein. Over 1,600 participants were included. The …
Sponsor: Zhongda Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New combo therapy shows promise for hard-to-treat lung cancer
Disease control CompletedThis study tested a new drug combination for people with a specific type of advanced lung cancer (EGFR-mutant non-small cell) that had stopped responding to standard targeted pills. The trial enrolled 95 adults and gave them two different combinations of immunotherapy (atezolizum…
Phase: PHASE2 • Sponsor: ETOP IBCSG Partners Foundation • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New combo therapy shows promise for tough liver cancer cases
Disease control CompletedThis study looked at adding a procedure called TACE (which blocks blood flow to tumors) to a mix of immunotherapy and anti-angiogenesis drugs for people with advanced liver cancer that has invaded major blood vessels. Over 2,600 participants were included to see if the triple com…
Sponsor: Zhongda Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New cocktail of chemo drugs shows promise for tough pancreatic cancer
Disease control CompletedThis study tested a combination of three chemotherapy drugs (paclitaxel protein bound, gemcitabine, and cisplatin) in 34 people with metastatic pancreatic cancer that had not been treated before. If the cancer got worse, a fourth drug (paricalcitol) was added. The goal was to see…
Phase: PHASE2 • Sponsor: HonorHealth Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New combo therapy shows promise for Tough-to-Treat kidney cancer
Disease control CompletedThis study tested whether adding an immunotherapy drug (nivolumab) to a targeted therapy (tivozanib) helps people with advanced kidney cancer live longer without their cancer growing. The trial included 343 adults whose cancer had worsened after one or two prior treatments, inclu…
Phase: PHASE3 • Sponsor: AVEO Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Rectal cancer patients may avoid surgery with new Chemo-Radiation combo
Disease control CompletedThis study tested a treatment plan for locally advanced rectal cancer that uses a short course of radiation followed by chemotherapy, aiming to avoid surgery. 39 patients were enrolled. The goal was to see if the cancer could be completely controlled without an operation, using a…
Phase: PHASE2 • Sponsor: Servicio de Salud Metropolitano Sur Oriente • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Experimental cancer drug injected directly into tumors shows early promise
Disease control CompletedThis early-phase trial tested a new drug called KL340399, which is injected directly into tumors to activate the immune system. It involved 6 adults with advanced solid tumors who had no other treatment options. The main goals were to check safety, find the right dose, and see if…
Phase: PHASE1 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New combo shows promise in shrinking stomach tumors before surgery
Disease control CompletedThis study tested whether adding the immunotherapy drug spartalizumab to standard chemotherapy (FLOT) helps shrink stomach cancer before surgery and prevent it from coming back. 67 adults with resectable stomach or gastroesophageal junction cancer received the combination before …
Phase: PHASE2 • Sponsor: Centre Francois Baclesse • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Experimental cancer drug KL340399 tested in 21 patients
Disease control CompletedThis early-phase trial tested a new drug called KL340399 in 21 adults with advanced solid tumors that had stopped responding to standard treatments. The drug works by activating the STING pathway to help the immune system fight cancer. The main goals were to check safety, find th…
Phase: PHASE1 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New drug shows promise in early liver cancer trial
Disease control CompletedThis early-phase study tested a drug called itacitinib in 19 adults with advanced liver cancer that had not responded to first-line treatment. The goal was to check the drug's safety and see if it could shrink tumors or slow cancer growth. Itacitinib works by blocking a protein t…
Phase: PHASE1 • Sponsor: Imperial College London • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Custom-Made vaccine targets pancreatic cancer in early human test
Disease control CompletedThis phase 1 trial tested a personalized vaccine made from each patient's unique cancer mutations (neoantigens) combined with an immune booster (poly-ICLC) in 33 people with pancreatic cancer. The vaccine was given after standard chemotherapy, either before or after surgery. The …
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Immunotherapy combo shows promise against tough rectal cancers
Disease control CompletedThis study tested whether adding an immunotherapy drug called APX005M to standard treatment helps people with advanced rectal cancer achieve a complete response (no cancer left after treatment). 58 adults with stage II or III rectal cancer at high risk took part. The goal was to …
Phase: PHASE2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Can a gout drug protect kidneys in cancer patients?
Disease control CompletedThis study tested pegloticase, a drug used for gout, in 10 cancer patients with high uric acid from tumor lysis syndrome. The goal was to see if it could quickly lower uric acid levels and protect kidney function. It was a small pilot trial to gather early data.
Phase: PHASE4 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Could selenium boost kidney cancer treatment?
Disease control CompletedThis trial tested a combination of two drugs—axitinib (a standard kidney cancer drug) and seleniomethionine (a form of selenium)—in 45 adults with advanced clear cell renal cell carcinoma that had spread. The goal was to find the safest dose and see if the combination could shrin…
Phase: PHASE1, PHASE2 • Sponsor: Mohammed Milhem • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Three-Dose radiation breakthrough for breast cancer patients
Disease control CompletedThis study tested a new way to give radiation to people with early-stage breast cancer. Instead of many sessions, patients received just three doses aimed only at the tumor area. The goal was to see if this shorter treatment is safe and works well. 77 patients took part, and the …
Phase: NA • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Targeted pill shows promise for rare genetic tumor types
Disease control CompletedThis phase 2 study tested the drug erdafitinib in 316 adults and children with advanced solid tumors that have specific FGFR gene mutations or fusions. The main goal was to see if the drug could shrink tumors. Participants took erdafitinib tablets daily. The study is now complete…
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New cancer drug HBM1020 tested in tiny early trial
Disease control CompletedThis early-phase study tested a new drug, HBM1020, in 17 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The drug was given by IV every three weeks. Because this is a Phase 1 trial, i…
Phase: PHASE1 • Sponsor: Harbour BioMed US, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Radiation-Chemo combo may let rectal cancer patients skip surgery
Disease control CompletedThis study tested whether a short course of radiation followed by chemotherapy could eliminate the need for surgery in people with early-stage rectal cancer. 63 patients were enrolled, and the treatment aimed for a complete clinical response, meaning no tumor could be found on ex…
Phase: NA • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New combo therapy shows promise in early trial for liver-metastatic colorectal cancer
Disease control CompletedThis early-phase study tested the safety of combining the immunotherapy drug pembrolizumab with precise, high-dose radiation (SBRT) to the liver in 15 adults with colorectal cancer that had spread only to the liver. The goal was to see if this combination could prevent the cancer…
Phase: PHASE1 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Radiation may buy time for liver cancer patients before stronger meds needed
Disease control CompletedThis study tested whether giving radiotherapy to liver cancer patients with limited tumor growth (oligo progression) could delay the need for second-line drug therapy. Thirty-six adults with advanced hepatocellular carcinoma received targeted radiation. The goal was to see if thi…
Sponsor: Shandong Cancer Hospital and Institute • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Experimental drug PRL3-ZUMAB shows promise in Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug called PRL3-ZUMAB in 14 people with advanced solid tumors (like stomach or liver cancer) that stopped responding to standard treatments. The drug was given every two weeks to see if it could shrink tumors or stop them from growing. Researchers also lo…
Phase: PHASE2 • Sponsor: National Cancer Centre, Singapore • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Exergaming and mediterranean diet tested for thyroid cancer recovery
Disease control CompletedThis study looked at whether playing active video games (exergaming) and following a Mediterranean diet could help people who had their thyroid removed due to cancer. 80 adults were split into four groups: one did exergaming, one followed the diet, one did both, and one had no ex…
Phase: NA • Sponsor: Nabil Mahmoud Ismail Abdel-Aal • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Electric field therapy combined with chemo shows promise for tough pancreatic cancer
Disease control CompletedThis pilot study tested a wearable device that delivers low-intensity electric fields (TTFields) together with immunotherapy (atezolizumab) and two chemotherapy drugs (gemcitabine and nab-paclitaxel) in 84 people with metastatic pancreatic cancer who had not received prior treatm…
Phase: PHASE2 • Sponsor: NovoCure Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New ALK inhibitor ensartinib tested in first human trial for lung cancer
Disease control CompletedThis study tested a new oral drug called ensartinib (X-396) for the first time in humans. It involved 131 people with advanced solid tumors, including those with ALK-positive non-small cell lung cancer. The goal was to find the safest dose and see if the drug could shrink tumors.…
Phase: PHASE1, PHASE2 • Sponsor: Xcovery Holdings, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New hope for tough ovarian cancer: targeted drug shows promise in trial
Disease control CompletedThis study tested a new drug, farletuzumab ecteribulin, which targets a protein found on many ovarian cancer cells. It was compared to standard chemotherapy in 106 women whose ovarian cancer had stopped responding to platinum-based treatments. The goal was to see if the new drug …
Phase: PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Radioactive drug shows promise against advanced cancers
Disease control CompletedThis study tested a new radioactive drug, 177Lu-NeoB, in 35 adults with advanced solid tumors that have a specific marker (GRPR). The goal was to check safety, find the best dose, and see if it shrinks tumors. It is an early-stage trial, so it focuses on safety and dosing, not a …
Phase: PHASE1, PHASE2 • Sponsor: Advanced Accelerator Applications • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New drug cocktail shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a combination of two cancer drugs, bortezomib and clofarabine, in 28 adults with advanced solid tumors, lymphomas, or myelodysplastic syndromes that had stopped responding to standard therapy. The main goal was to find the safest dose and check for s…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New drug duo targets Hard-to-Treat colorectal cancer
Disease control CompletedThis phase 3 trial tested whether combining sotorasib (a pill) and panitumumab (an infusion) can slow tumor growth better than standard chemotherapy in 160 adults with metastatic colorectal cancer that has a specific KRAS G12C mutation. Participants were randomly assigned to rece…
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New drug ProAgio tested in patients with advanced cancers
Disease control CompletedThis early-stage trial tested a new drug, ProAgio, in 46 people with advanced solid tumors, including pancreatic cancer, who had already tried other treatments. The main goal was to find a safe dose and check for side effects. The study did not aim to cure the disease, but to con…
Phase: PHASE1 • Sponsor: ProDa BioTech, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Triple-Drug cocktail aims to beat stomach cancer
Disease control CompletedThis phase 3 trial tested whether adding lenvatinib and pembrolizumab to standard chemotherapy helps people with advanced gastroesophageal cancer live longer. About 895 participants received either the new combination or chemo alone. The study is complete, and results will show i…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New cocktail of drugs shows promise for tough pancreatic cancer
Disease control CompletedThis study tested a combination of four drugs (tadalafil, pembrolizumab, ipilimumab, and CRS-207) in 17 people with advanced pancreatic cancer that had worsened after at least one round of chemotherapy. The goal was to see if the combination was safe and could shrink tumors. The …
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Gene-Tailored therapy shows promise for advanced lung cancer
Disease control CompletedThis study tested whether customizing chemotherapy based on specific gene mutations (EGFR and BRCA1) could improve outcomes for 153 patients with advanced lung adenocarcinoma. Participants received treatments matched to their tumor's genetic profile. The goal was to see if this p…
Phase: NA • Sponsor: Spanish Lung Cancer Group • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Lung cancer trial matches drugs to genes: a step toward personalized treatment
Disease control CompletedThis trial tested several targeted drugs in people with non-small cell lung cancer whose tumors had specific genetic changes. The goal was to see if these drugs could shrink tumors or delay cancer growth. Over 400 participants received treatment based on their tumor's genetic pro…
Phase: PHASE2 • Sponsor: University of Birmingham • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Experimental drug combo targets Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a new drug called AZD8186 combined with the chemotherapy docetaxel in 23 patients with advanced solid tumors that have PTEN or PIK3CB gene mutations. The main goal was to find the safest dose and understand side effects. The study is complete, but re…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Immunotherapy shows promise against Hard-to-Treat colorectal cancer
Disease control CompletedThis phase 2 study tested the immunotherapy drug prolgolimab in 30 people with a specific type of colorectal cancer (MSI/dMMR) that had not spread. Participants received the drug for 6 months before planned surgery. The main goal was to see if the cancer completely disappeared in…
Phase: PHASE2 • Sponsor: Blokhin's Russian Cancer Research Center • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Double radiation attack shows promise for returning prostate cancer
Disease control CompletedThis study tested whether adding a radioactive drug (radium-223) to standard targeted radiation (SBRT) can delay cancer progression in men whose prostate cancer has returned in a few bone spots but hasn't yet become hormone-resistant. Twelve men participated, receiving either the…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New drug combo shows promise for Tough-to-Treat endometrial cancer
Disease control CompletedThis phase II trial tested whether combining two drugs, pembrolizumab and olaparib, could help people with persistent or recurrent endometrial cancer or carcinosarcoma. The study enrolled 26 participants and looked at how many responded to treatment and what side effects occurred…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Experimental antibody HH-101 tested in 12 patients with advanced cancers
Disease control CompletedThis early-stage trial tested an experimental drug called HH-101 in 12 people with advanced solid tumors that had not responded to standard treatments. The main goal was to check the drug's safety and find the right dose. Participants received HH-101 as an IV infusion every three…
Phase: PHASE1 • Sponsor: Huahui Health • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New flavored drink helps cancer patients keep weight on during treatment
Disease control CompletedThis study tested three flavors of Supportan® drink (Tropical Fruits, Cappuccino, and Pineapple-Coconut) in 123 cancer patients undergoing chemotherapy, radiotherapy, immunotherapy, or targeted therapy. Patients drank two bottles daily for four weeks alongside their normal diet. …
Phase: NA • Sponsor: Fresenius Kabi Taiwan Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New radiation therapy shows promise for Tough-to-Treat kidney cancer
Disease control CompletedThis study tested a new treatment for people with advanced clear cell kidney cancer that had spread and stopped responding to standard therapies. Six adults received four injections of a radioactive drug (177Lu-PSMA-1) that targets cancer cells. The goal was to check safety and s…
Phase: PHASE1, PHASE2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Keytruda may keep liver cancer at bay after surgery
Disease control CompletedThis large phase 3 trial tested whether the immunotherapy drug pembrolizumab (Keytruda) can prevent liver cancer from coming back in people who had successful surgery or ablation. 959 participants received either pembrolizumab or a placebo every three weeks. The study measured ho…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New combo therapy shows promise for Tough-to-Treat colon cancer
Disease control CompletedThis early-phase study tested a combination of two drugs, cabozantinib and TAS-102, in 15 people with advanced colorectal cancer that had spread and stopped responding to standard treatments. The main goal was to find the safest dose and identify side effects. The study is comple…
Phase: PHASE1 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Exercise program tested to keep colon cancer at bay
Disease control CompletedThis study tested whether a 3-year physical activity program could help prevent colon cancer from coming back in 889 patients who had surgery and chemotherapy for high-risk stage II or stage III colon cancer. Participants were randomly assigned to either the exercise program plus…
Phase: NA • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New combo therapy shows promise for tough-to-treat liver cancer
Disease control CompletedThis study tested a combination of proton beam radiotherapy followed by two drugs (Tecentriq and Avastin) in 63 adults with advanced liver cancer that had spread into the portal vein. The goal was to see if this approach could help control the cancer and improve survival. Partici…
Phase: PHASE2 • Sponsor: Samsung Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New 'Bottom-Up' surgery for rectal cancer could mean faster recovery
Disease control CompletedThis study tested a newer, less invasive surgery called ETAP (done through the anus) against standard laparoscopic surgery (done through the belly) for low rectal cancer. 226 adults took part. The goal was to see if ETAP is as good at removing all cancer while possibly leading to…
Phase: PHASE3 • Sponsor: Institut Paoli-Calmettes • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug cocktail tested for tough pancreatic cancer
Disease control CompletedThis early-phase study tested a combination of three drugs (gemcitabine, capecitabine, and erlotinib) in 30 people with advanced pancreatic cancer that had already been treated. The main goal was to find the safest dose and understand side effects. This is not a cure, but aims to…
Phase: PHASE1 • Sponsor: Centre Antoine Lacassagne • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug cocktail shows promise against tough pancreatic cancer
Disease control CompletedThis study tested a combination of four drugs (paclitaxel protein bound, gemcitabine, cisplatin, and paricalcitol) given before surgery to people with pancreatic cancer that could or could not be removed. The goal was to see if the treatment could shrink tumors and improve surgic…
Phase: PHASE2 • Sponsor: HonorHealth Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Custom-Made cancer vaccine shows promise in early trial
Disease control CompletedThis completed phase I/IIb trial tested a personalized vaccine made from each patient's unique tumor mutations. Eight adults with advanced solid tumors or high recurrence risk received the vaccine alongside an immune booster and later checkpoint inhibitors. The goal was to see if…
Phase: PHASE1, PHASE2 • Sponsor: Seqker Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New combo therapy shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a combination of three drugs—vemurafenib, cetuximab, and irinotecan—in 47 people with advanced solid tumors that have a specific BRAF V600 mutation and could not be removed by surgery or had spread. The main goal was to find the safest dose and under…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New cancer drug shows promise in early trial for Tough-to-Treat tumors
Disease control CompletedThis study tested a new drug called FF-10502-01 in 106 adults with advanced solid tumors or lymphomas that had stopped responding to standard treatments. The goal was to find the safest dose and see if the drug could shrink tumors or slow disease progression. While not a cure, th…
Phase: PHASE1, PHASE2 • Sponsor: Fujifilm Pharmaceuticals U.S.A., Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug targets tough childhood cancers with genetic flaws
Disease control CompletedThis phase 2 trial tested the drug samotolisib in 18 children and young adults with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that had spread, returned, or stopped responding to treatment. Only patients whose tumors had specific mutations in the TSC or…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug combo helps High-Risk kidney cancer patients avoid full kidney removal
Disease control CompletedThis study tested a combination of two drugs (cadonilimab and lenvatinib) given before surgery to 39 people with kidney cancer that was difficult to operate on while saving the kidney. The goal was to shrink the tumor enough to allow a partial, kidney-sparing surgery instead of r…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Triple chemo cocktail shows promise against tough pancreatic cancer
Disease control CompletedThis phase II trial tested a combination of three chemotherapy drugs (nab-paclitaxel, cisplatin, and gemcitabine) in 42 people with metastatic pancreatic cancer that had not been treated before. The main goal was to see how many patients were alive after 12 months. The study also…
Phase: PHASE2 • Sponsor: HonorHealth Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New liposomal chemo cocktail takes on pancreatic cancer
Disease control CompletedThis Phase 3 trial tested a new combination of chemotherapy drugs—irinotecan liposome, oxaliplatin, 5-fluorouracil, and leucovorin—against the standard treatment (nab-paclitaxel plus gemcitabine) in 770 people with metastatic pancreatic cancer who had not received prior chemother…
Phase: PHASE3 • Sponsor: Ipsen • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
Radiation zaps liver tumors in patients too sick for surgery
Disease control CompletedThis pilot study tested a precise type of radiation called stereotactic body radiation therapy (SBRT) in 20 adults with liver cancer that could not be surgically removed. The goal was to see if the treatment is safe and to measure how long patients survive. The approach aims to d…
Phase: NA • Sponsor: Montefiore Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Triple therapy shows promise for advanced liver cancer
Disease control CompletedThis study tested a triple combination treatment for advanced liver cancer that has spread. It combines a procedure called TACE (which blocks blood flow to the tumor) with immunotherapy drugs (PD-1/PD-L1 inhibitors) and targeted therapies (VEGF-TKI or bevacizumab). The goal is to…
Sponsor: Zhongda Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Triple therapy shows promise for intermediate liver cancer
Disease control CompletedThis study tested a three-pronged approach for intermediate-stage liver cancer: a procedure that blocks blood flow to the tumor (TACE), immunotherapy drugs that help the immune system fight cancer, and targeted drugs that stop blood vessel growth. Over 900 patients participated. …
Sponsor: Zhongda Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Liver cancer patients get new hope: study tests two drug cocktails after first treatment fails
Disease control CompletedThis study looked at 200 people with advanced liver cancer whose first treatment (bevacizumab plus sintilimab) stopped working. Researchers compared two second-line options: a PD-1 inhibitor combined with either lenvatinib or regorafenib. The goal was to see which combo works bet…
Phase: NA • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New combo therapy shows promise for tough liver cancer cases
Disease control CompletedThis study tested a new treatment for advanced liver cancer that has spread into the major blood vessels of the liver. Thirty patients received a special type of radiation along with an immunotherapy drug called tislelizumab. The goal was to see if this combination could help pat…
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New drug tested for advanced cancers: early results
Disease control CompletedThis early-phase trial tested a new drug called NOV140101 in 32 adults with advanced solid tumors that had spread or could not be removed by surgery. The main goals were to find the safest dose and check for side effects. The study is complete, but it was too small to determine i…
Phase: PHASE1 • Sponsor: Idience Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New hope for stomach cancer: drug cocktail shows promise in early trial
Disease control CompletedThis study tested a mix of three drugs—trastuzumab deruxtecan (a targeted therapy), nivolumab (an immunotherapy), and chemotherapy—in 30 people with untreated HER2-low stomach or gastroesophageal junction cancer. The goal was to first find a safe dose and then see how well it shr…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Center Hospital East • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Immunotherapy combo before kidney surgery shows promise in small trial
Disease control CompletedThis early-phase study tested two immunotherapy drugs (spartalizumab and canakinumab) given before surgery to 17 people with localized clear cell kidney cancer. The main goal was to see if this approach was safe and did not delay surgery. The study also looked at how the drugs af…
Phase: EARLY_PHASE1 • Sponsor: Columbia University • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Tailored chemo doses may help seniors fight pancreatic cancer while staying independent
Disease control CompletedThis study tested a chemotherapy cocktail called FOLFIRINOX in 72 patients aged 70 or older with metastatic pancreatic cancer. The doses were adjusted based on each person's genetics to reduce side effects while still fighting the tumor. The goal was to see if this approach could…
Phase: PHASE2 • Sponsor: Institut Cancerologie de l'Ouest • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New antibody drug shows promise in early cancer trial
Disease control CompletedThis early-phase study tested a new drug called TQB2210 in 16 people with advanced cancers that had not responded to other treatments. The drug is a lab-made antibody that targets a specific protein (FGFR2b) on cancer cells to block their growth. The main goals were to find a saf…
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Drug shows promise for kidney cancer brain metastases in early trial
Disease control CompletedThis phase 2 trial tested the drug sunitinib in 21 patients with kidney cancer that had spread to the brain. The goal was to see if the drug could shrink brain tumors by blocking blood flow and cell growth. Researchers measured how many patients had a response after two treatment…
Phase: PHASE2 • Sponsor: Institut Claudius Regaud • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Immunotherapy drug shows promise in bile duct cancer trial
Disease control CompletedThis Phase 3 trial tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (gemcitabine and cisplatin) helps people with advanced bile duct cancer live longer. The study enrolled 158 Chinese adults with cancer that had spread or could not be removed by…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Cord blood cells engineered to fight stomach and pancreatic cancers
Disease control CompletedThis early-phase study tested a new treatment using immune cells from cord blood, modified to target a protein called Claudin18.2 found on some cancer cells. Ten adults with advanced stomach or pancreatic cancer who had no other options received these cells to find the safest dos…
Phase: PHASE1 • Sponsor: Zhejiang Provincial People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New Double-Action antibody shows promise against Hard-to-Treat cancers
Disease control CompletedThis phase 2 trial tested an experimental drug called HX009 in 20 adults with advanced solid tumors that had stopped responding to standard treatments. HX009 is a bifunctional antibody designed to block two proteins (CD47 and PD-1) that help tumors hide from the immune system. Th…
Phase: PHASE2 • Sponsor: Hangzhou Hanx Biopharmaceuticals, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug takes on tough pancreatic cancer
Disease control CompletedThis study tested a new drug called HCW9218 in 21 people with advanced pancreatic cancer that had stopped responding to standard treatments. The drug is designed to boost the immune system and block a protein that helps tumors grow. The main goals were to check safety and find th…
Phase: PHASE1, PHASE2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New hope for kids with Hard-to-Treat cancers: targeted drug shows promise
Disease control CompletedThis study tested a drug called tazemetostat in 20 children whose cancers had come back or weren't responding to treatment. The children had specific gene changes (EZH2, SMARCB1, or SMARCA4) in their tumors. The goal was to see if the drug could shrink or slow the growth of these…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New radiation approach targets inoperable pancreatic tumors
Disease control CompletedThis early-phase trial tested a new type of radiation called carbon ion therapy for people with locally advanced pancreatic cancer that cannot be removed by surgery. Fourteen participants received increasing doses of carbon ion radiation along with chemotherapy. The main goal was…
Phase: PHASE1 • Sponsor: Montefiore Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Can a drug shrink precancerous breast cells before surgery?
Disease control CompletedThis study tested whether a drug called ruxolitinib can reduce abnormal breast cells in people with high-risk or precancerous breast conditions like DCIS or atypical hyperplasia. Half of the 84 participants took ruxolitinib for about 15 days before surgery, and the other half too…
Phase: PHASE2 • Sponsor: Julie Nangia • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug cocktail shows promise for tough ovarian cancers
Disease control CompletedThis study tested a combination of two drugs, AZD6738 and olaparib, in 123 women with recurrent ovarian cancer. The goal was to see if the combo is safe and how well it shrinks tumors or delays cancer growth. Participants had either platinum-sensitive or platinum-resistant cancer…
Phase: PHASE2 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Double antenna ablation shows promise for small liver tumors
Disease control CompletedThis study tested a new way to destroy small liver tumors using two microwave antennas at once, compared to the standard single antenna method. Twenty patients with small hepatocellular carcinoma (liver cancer) were treated. The goal was to see if the two-antenna approach could m…
Phase: NA • Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New hope: hepatitis c drugs after liver cancer treatment
Disease control CompletedThis study tested whether interferon-free drug combinations can cure hepatitis C in 150 people who had been successfully treated for liver cancer. Participants took pills like sofosbuvir and ribavirin for 12 weeks. The main goal was to see if the virus stayed undetectable 12 week…
Phase: PHASE3 • Sponsor: National Hepatology & Tropical Medicine Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New needle combo zaps returning liver tumors after failed chemo
Disease control CompletedThis study tested a special type of radiofrequency ablation using two cooled needles that also release saline to treat liver cancer that came back after chemoembolization. The goal was to see if this technique could better destroy the tumor and prevent it from growing back. One h…
Phase: NA • Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New hope for elderly kidney cancer patients: cabozantinib under review
Disease control CompletedThis study looked at how safe and effective the drug Cabozantinib is for people aged 70 and older with advanced kidney cancer. Researchers tracked side effects and tumor response in 100 participants. The goal was to see if this treatment works well in older patients who have alre…
Sponsor: Istituto Oncologico Veneto IRCCS • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Promising drug combo targets Hard-to-Treat salivary cancer
Disease control CompletedThis phase 2 trial tested darolutamide, a drug that blocks male hormones, in 57 people with a rare type of salivary gland cancer that has male hormone receptors. Some patients received darolutamide alone, while others also got goserelin to lower hormone levels. The goal was to se…
Phase: PHASE2 • Sponsor: National Cancer Center Hospital East • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Rapid Finger-Prick test could help shield cancer patients from COVID-19
Diagnosis CompletedThis study tested a quick finger-prick blood test to see if cancer patients had been infected with COVID-19 in the past. Researchers enrolled 214 adults being treated for cancer. The goal was to find out how many had antibodies, including those without symptoms, to help clinics k…
Phase: NA • Sponsor: Centre Antoine Lacassagne • Aim: Diagnosis
Last updated Jul 04, 2026 00:00 UTC
-
Simple blood or urine test could spot kidney cancer early
Diagnosis CompletedThis study collects blood, tissue, and urine from about 589 people with different types of kidney or urinary tract tumors, plus healthy volunteers. Researchers are looking for special DNA markers (methylated DNA) that could help detect these cancers earlier and more accurately. T…
Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
New PET tracer could spot hidden thyroid cancer
Diagnosis CompletedThis study tested whether a special PET scan tracer called 18F-DOPA can better detect leftover medullary thyroid cancer in lymph nodes after surgery, compared to standard imaging. Twenty-four adults with elevated thyrocalcitonin levels (a sign of residual disease) received the tr…
Phase: NA • Sponsor: Institut Claudius Regaud • Aim: Diagnosis
Last updated Jun 28, 2026 00:00 UTC
-
New scan could reveal hidden cancer cells
Diagnosis CompletedThis early study tested a radioactive imaging agent called [99mTc]Tc(CO)3-(HE)3-Ec1 in 10 adults with solid tumors. The agent is designed to attach to EpCAM receptors on cancer cells, making them visible on SPECT scans. Researchers aimed to see where the agent goes in the body, m…
Phase: PHASE1 • Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences • Aim: Diagnosis
Last updated Jun 27, 2026 14:03 UTC
-
New blood test aims to spot prostate cancer cells earlier
Diagnosis CompletedThis study tested a new blood test called EPISPOT to find prostate cancer cells in the blood of 361 men with localized prostate cancer before they received any treatment. The goal was to see if this test could predict remission better than an existing test called CellSearch. The …
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
New scan spots hidden oxygen shortage in pancreatic tumors
Diagnosis CompletedThis study tested whether a PET scan using a tracer called 18F-FAZA can measure low oxygen levels (hypoxia) in pancreatic cancer. Hypoxia can affect how the cancer grows and responds to treatment. 48 adults with pancreatic cancer received the scan, and researchers also collected …
Sponsor: University Health Network, Toronto • Aim: Diagnosis
Last updated Jun 27, 2026 13:07 UTC
-
New blood test may spot liver cancer sooner in High-Risk patients
Diagnosis CompletedThis study looked at 639 adults with cirrhosis to see if a blood test called mSEPT9 can detect liver cancer (hepatocellular carcinoma) better than the current standard test (AFP). Participants gave an extra blood sample during routine care, and researchers compared how well each …
Phase: NA • Sponsor: Central Hospital, Nancy, France • Aim: Diagnosis
Last updated Jun 27, 2026 13:07 UTC
-
New biopsy technique may spot hidden abdominal cancers without major surgery
Diagnosis CompletedThis study looked at how well a special biopsy method called EUS-FNB can diagnose hard-to-reach tumors in the abdomen, such as those near the bile duct or small intestine. Researchers reviewed data from 131 patients who had this procedure over 10 years. The goal was to see if thi…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Diagnosis
Last updated Jun 27, 2026 13:01 UTC
-
Can a special MRI spot kidney cancer better?
Diagnosis CompletedThis study tested whether a special type of MRI, called perfusion MRI, can help doctors find and diagnose kidney tumors more accurately. 75 people with kidney cancer or suspected kidney tumors took part. The goal was to see if this imaging method could predict tumor type and how …
Phase: NA • Sponsor: Rutgers, The State University of New Jersey • Aim: Diagnosis
Last updated Jun 27, 2026 13:01 UTC
-
New handheld device could spot heart and diabetes problems in cancer patients
Diagnosis CompletedThis study tested a handheld device that uses a single wave to measure how well the heart pumps blood and how stiff the arteries are. Researchers compared it to standard echocardiography in 159 cancer patients. The goal was to see if the device could also help identify patients a…
Sponsor: City of Hope Medical Center • Aim: Diagnosis
Last updated Jun 27, 2026 13:01 UTC
-
New imaging agent could sharpen pancreatic cancer detection
Diagnosis CompletedThis study tested a radioactive tracer called [68Ga]FAPI-46, used with a PET scan, to see if it can better detect pancreatic cancer cells. 63 adults with early-stage pancreatic cancer received the tracer before surgery. The goal was to see how well the scan matches the actual can…
Phase: PHASE2 • Sponsor: SOFIE • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
AI and PET scans join forces to grade cancer without a biopsy
Diagnosis CompletedThis completed study tested whether combining PET/MRI scans with machine learning could better assess how aggressive prostate cancer and other solid tumors are. Researchers enrolled 50 adults with prostate cancer, liver cancer, brain tumors, or kidney cancer. The goal was to see …
Sponsor: Ciprian Catana, MD, PhD • Aim: Diagnosis
Last updated Jun 27, 2026 12:37 UTC
-
Which biopsy method best spots bile duct cancer?
Diagnosis CompletedThis study looked at different ways to take tissue samples from the bile duct during a procedure called ERCP. The goal was to see which method is most accurate for finding cancer. 327 adults with unclear bile duct narrowing took part. Researchers compared several biopsy technique…
Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Jun 27, 2026 12:36 UTC
-
New ultrasound trick spots liver cancer treatment success days earlier
Diagnosis CompletedThis study tested a new ultrasound technique (Side-by-Side Contrast-Enhanced Ultrasound) to see if it could accurately check whether microwave ablation fully destroyed liver tumors just 1-3 days after treatment. Researchers compared it to standard contrast-enhanced ultrasound in …
Phase: NA • Sponsor: The First Hospital of Jilin University • Aim: Diagnosis
Last updated Jun 27, 2026 12:35 UTC
-
Glow-in-the-Dark dye could help surgeons spot hidden breast cancer
Diagnosis CompletedThis study tested a new imaging dye called LS301-IT in 22 women with early-stage breast cancer (DCIS or stage I-II) who were having a partial mastectomy. The dye is injected into a vein before surgery to make cancer cells glow, helping surgeons see and remove them more accurately…
Phase: PHASE1, PHASE2 • Sponsor: Integro Theranostics • Aim: Diagnosis
Last updated Jun 27, 2026 12:35 UTC
-
AI takes on radiologists: can a computer beat the standard for liver cancer diagnosis?
Diagnosis CompletedThis study tested a new artificial intelligence (AI) algorithm against the standard LI-RADS criteria for diagnosing liver cancer (hepatocellular carcinoma) on CT scans. Researchers enrolled 300 people at risk for liver cancer who had a new liver nodule found on ultrasound. The go…
Phase: NA • Sponsor: The University of Hong Kong • Aim: Diagnosis
Last updated Jun 27, 2026 12:33 UTC
-
New MRI method could spare thousands from unnecessary kidney surgery
Diagnosis CompletedThis completed study tested whether a special type of MRI (multiparametric MRI) can accurately tell the difference between benign and malignant small kidney tumors. About 387 adults with small solid kidney masses (1.5-4 cm) were scanned before surgery or biopsy. The goal was to s…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Diagnosis
Last updated Jun 27, 2026 12:32 UTC
-
New digital scope could help rectal cancer patients avoid surgery
Diagnosis CompletedThis study tested a new digital scope called LUMENEYE to see if it can better measure how much a rectal tumor has shrunk after chemotherapy and radiation. 82 patients who were good candidates for organ preservation were included. The goal was to see if the scope could help doctor…
Sponsor: Bordeaux Colorectal Institute Academy • Aim: Diagnosis
Last updated Jun 27, 2026 12:30 UTC
-
Could a new PET scan help match pancreatic cancer patients to the right therapy?
Diagnosis CompletedThis phase 1 trial tested a new radioactive imaging agent called 64Cu-DOTA-ECL1i to see if it can detect a protein called CCR2 in pancreatic tumors using PET scans. The study involved 69 adults with pancreatic ductal adenocarcinoma at various stages. The goal was to see if the sc…
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Diagnosis
Last updated Jun 27, 2026 12:30 UTC
-
Can MRI better spot early breast cancer spread?
Diagnosis CompletedThis study looked at whether MRI can more accurately measure the size of ductal carcinoma in situ (a very early form of breast cancer) compared to standard mammography. Forty women with the condition had MRI scans before surgery. Researchers then compared the MRI results with the…
Phase: NA • Sponsor: Centre Antoine Lacassagne • Aim: Diagnosis
Last updated Jun 27, 2026 12:29 UTC
-
New blood markers could revolutionize liver cancer diagnosis
Diagnosis CompletedThis study looked at blood samples from 573 people to find new markers that could diagnose liver cancer more accurately. Researchers compared samples from patients with liver cancer, those with other liver conditions, and people with hepatitis infections. The goal is to improve u…
Sponsor: Stanford University • Aim: Diagnosis
Last updated Jun 27, 2026 12:08 UTC
-
Can a pill shield ears from chemo damage?
Prevention CompletedThis study tests whether the drug SENS-401 can prevent hearing loss caused by cisplatin, a common chemotherapy. Adults with cancer who are scheduled to receive cisplatin take SENS-401 before, during, and after treatment. Hearing is measured with a standard test to see if the drug…
Phase: PHASE2 • Sponsor: Sensorion • Aim: Prevention
Last updated Jul 04, 2026 00:00 UTC
-
New catheter lock could slash infection risk for cancer patients
Prevention CompletedThis study tested whether a taurolidine-citrate solution (TauroLock) placed in the catheter between treatments can prevent bloodstream infections in adults with solid tumors receiving IV anti-cancer therapy. 162 patients were randomly assigned to get either the TauroLock solution…
Phase: NA • Sponsor: Centre Hospitalier Régional Metz-Thionville • Aim: Prevention
Last updated Jun 27, 2026 14:02 UTC
-
Can the HPV vaccine stop cervical abnormalities from returning after surgery?
Prevention CompletedThis study looked at whether giving the Gardasil 9 HPV vaccine to women at the same time as surgery for abnormal cervical cells (CIN) can help clear the virus and prevent future infections. About 1,100 women aged 18-55 took part. The goal was to see if the vaccine reduces the cha…
Phase: PHASE3 • Sponsor: Imperial College London • Aim: Prevention
Last updated Jun 27, 2026 12:28 UTC
-
Laparoscopic showdown: which surgical technique helps gastric cancer patients recover better?
Symptom relief CompletedThis trial compares two minimally invasive surgical techniques for removing the lower part of the stomach in people with gastric cancer: laparoscopy-assisted distal gastrectomy (LADG) and totally laparoscopic distal gastrectomy (TLDG). The goal is to see which approach leads to b…
Phase: NA • Sponsor: Fudan University • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
Could tiny needles tame Chemo's Gut-Wrenching side effect in kids?
Symptom relief CompletedThis study tests whether acupuncture using tiny, semi-permanent needles can prevent diarrhea caused by the chemotherapy drug irinotecan in children with solid tumors. About 22 children will receive the acupuncture during their second round of chemo, and researchers will measure p…
Phase: NA • Sponsor: Fundació Sant Joan de Déu • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
Remote diet coaching tested for pancreatic cancer patients
Symptom relief CompletedThis study tested whether a remote nutrition coaching program is practical and well-liked by people with pancreatic cancer who are undergoing chemotherapy. Forty participants were asked to complete online food questionnaires and attend coaching sessions over 12 weeks. The goal wa…
Phase: NA • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
Simple relaxation technique may improve sleep in cancer patients
Symptom relief CompletedThis study tested whether Benson relaxation exercises can improve sleep quality in cancer patients. 72 adults with cancer were randomly assigned to do relaxation exercises or receive a sleep hygiene booklet. The goal was to see if this simple, non-drug method could help with slee…
Phase: NA • Sponsor: Atlas University • Aim: Symptom relief
Last updated Jun 27, 2026 14:03 UTC
-
Acupressure may ease fatigue in young cancer survivors
Symptom relief CompletedThis study tested whether young cancer survivors (ages 15-39) could learn to do acupressure on themselves to reduce fatigue. 42 people who had finished cancer treatment at least three months ago and still felt tired took part. They used a special tool and a phone app to apply pre…
Phase: NA • Sponsor: University of Michigan Rogel Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Could a tiny dose of this drug help men with prostate cancer avoid surgery?
Symptom relief CompletedThis study tested whether a very low dose of apalutamide, taken for 3-4 weeks before prostate removal surgery, could lower PSA levels in 34 men with early-stage prostate cancer. The goal was to see if the drug blocks testosterone's effect on cancer growth. If it works, it might o…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Buzzy, coaching, or kaleidoscope: which best calms kids during cancer shots?
Symptom relief CompletedThis study tested three non-drug methods to reduce pain, fear, and anxiety during subcutaneous injections in 45 children aged 6–12 with cancer. The approaches were Buzzy® (a device that vibrates and cools the skin), a cognitive-behavioral coaching package, and a kaleidoscope for …
Phase: NA • Sponsor: Kocaeli University • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Remote strength training aims to boost endometrial cancer survivorship in rural areas
Symptom relief CompletedThis study tests a 10-week, remotely supervised strength training program for endometrial cancer survivors living in rural or underserved areas. The goal is to see if the program is practical and helps improve physical function and quality of life. Participants exercise twice a w…
Phase: NA • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Short physiotherapy program shows promise for palliative cancer patients
Symptom relief CompletedThis study tested whether a one-week physiotherapy program could improve movement, walking, and daily independence in 32 advanced cancer patients receiving palliative care. The program included exercises, mobility training, and breathing therapy tailored to each patient. Research…
Phase: NA • Sponsor: University of Jazan • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Pump education eases chemo anxiety, study finds
Symptom relief CompletedThis study looked at whether teaching cancer patients about their portable chemotherapy pump (elastomeric pump) can make them feel more comfortable and less anxious. 70 adults receiving 5-FU treatment were split into two groups: one got extra education and a booklet, the other go…
Phase: NA • Sponsor: Biruni University • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Punjabi cancer patients get a custom exercise boost
Symptom relief CompletedThis pilot study tested whether a 12-week exercise program designed for Punjabi-speaking South Asian cancer patients and their support persons is practical and well-liked. Twelve participants did twice-weekly exercise sessions and filled out questionnaires. The goal was to see if…
Phase: NA • Sponsor: University of Calgary • Aim: Symptom relief
Last updated Jun 27, 2026 13:06 UTC
-
New drip combo aims to stop chemo nausea in kids
Symptom relief CompletedThis phase 3 trial tested whether giving a continuous, slow infusion of ondansetron (a common anti-nausea drug) plus dexamethasone (a steroid) could better control nausea and vomiting in children undergoing chemotherapy. The study enrolled 28 children aged 1 day to 18 years with …
Phase: PHASE3 • Sponsor: Immune Oncology Research Institute • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
Inner strength boosts morale in elderly cancer patients
Symptom relief CompletedThis study tested a one-month program designed to build inner strength in elderly cancer patients who were feeling demoralized. 66 patients took part, with half receiving the program plus standard care and the other half receiving standard care alone. The goal was to see if the p…
Phase: NA • Sponsor: Peking Union Medical College Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 13:03 UTC
-
Virtual reality goggles could take the sting out of cancer port needles
Symptom relief CompletedThis study tested whether using virtual reality goggles during the insertion of a port needle (a common procedure for chemotherapy) can improve comfort and satisfaction in cancer patients. 92 adults with stage I-III cancer were randomly assigned to either standard care or standar…
Phase: NA • Sponsor: Uludag University • Aim: Symptom relief
Last updated Jun 27, 2026 13:03 UTC
-
Yoga with a shared background may ease Cancer's toll for black survivors
Symptom relief CompletedThis study tested whether a yoga program taught by a Black instructor could help Black cancer survivors feel better and improve their quality of life. 13 adults who had cancer in the last 5 years took part. The goal was to see if this approach was acceptable and helpful for manag…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
New Low-Dose pain patch aims to ease cancer suffering
Symptom relief CompletedThis study tested a low-dose fentanyl patch in 14 cancer patients in Taiwan to see if it is safe and tolerable for managing pain. The patch delivers pain medicine through the skin over 28 days. The main goal was to see how many patients dropped out due to side effects, with the h…
Phase: PHASE4 • Sponsor: Janssen-Cilag Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
Cancer pain relief without the sickness: new hope from an old drug
Symptom relief CompletedThis study tested whether naldemedine, a drug already used for opioid-induced constipation, can also prevent nausea and vomiting when cancer patients start strong painkillers. 120 adults with cancer who were beginning opioid therapy took either naldemedine or a placebo for up to …
Phase: PHASE4 • Sponsor: International University of Health and Welfare • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
New drug may ease severe skin rashes in cancer patients
Symptom relief CompletedThis study tested whether the drug benralizumab can safely reduce skin rashes caused by cancer treatments like checkpoint inhibitors. The goal was to lower the number of high-grade rashes to milder ones, which could improve quality of life and help patients stay on their cancer t…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 13:01 UTC
-
Zapping away stress and cigarettes: new hope for cancer survivors
Symptom relief CompletedThis study tested whether a gentle, non-invasive brain stimulation technique called tDCS could help cancer survivors who smoke feel less distressed and smoke fewer cigarettes. 43 participants used the device at home via telehealth. The main goal was to see if people found the dev…
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
New spanish therapy helps cancer survivors find purpose after treatment
Symptom relief CompletedThis study tested a Spanish adaptation of Meaning-Centered Psychotherapy for 92 adults who completed cancer treatment. The therapy aims to help patients find meaning in life and reduce anxiety. Participants attended eight group sessions focused on sources of meaning, facing the f…
Phase: NA • Sponsor: University of Valencia • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
String-Attached stent may ease bile duct cancer surgery prep
Symptom relief CompletedThis pilot study tested a plastic stent with a retrieval string to drain bile in 40 people with resectable bile duct cancer. The goal was to see if the stent could safely reduce bile buildup before surgery. Researchers measured serious complications and how well the stent worked.
Phase: NA • Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
Lower dose of olanzapine may ease chemo nausea with less drowsiness
Symptom relief CompletedThis study looked at 2,000 adults with solid tumors to find the best dose of olanzapine for preventing nausea and vomiting caused by strong chemotherapy. Researchers compared 2.5 mg, 5 mg, and 10 mg doses to see which works best with the fewest side effects like daytime sleepines…
Sponsor: Shandong Cancer Hospital and Institute • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
Can learning to solve problems ease cancer distress in young adults?
Symptom relief CompletedThis study tested a program called Bright IDEAS-YA that teaches young adults with cancer a step-by-step approach to solving problems. The goal was to see if it could reduce symptoms of depression and anxiety and improve quality of life. 344 young adults (ages 18-39) newly diagnos…
Phase: NA • Sponsor: Rutgers, The State University of New Jersey • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
Can music ease anxiety for End-of-Life cancer patients?
Symptom relief CompletedThis study tested a music therapy program called Meraki for cancer patients receiving palliative care. The goal was to see if three music sessions could improve emotional well-being, reduce anxiety and depression, and boost quality of life. Researchers enrolled 80 patients and me…
Phase: NA • Sponsor: University of Valencia • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
Laughter yoga: a surprising way to help cancer patients feel better?
Symptom relief CompletedThis study looked at whether laughter yoga could help cancer patients going through chemotherapy. 55 patients were split into two groups: one did weekly 40-minute laughter yoga sessions for four weeks, while the other received standard care. After four weeks, the laughter yoga gr…
Phase: NA • Sponsor: Ataturk University • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
Cancer patients boost Well-Being by tapping into personal strengths
Symptom relief CompletedThis study tested a 3-week program that helps cancer patients identify their personal strengths (like hobbies, social support, or personal qualities) and use them to cope better. 32 adults with different cancers took part in card-sorting sessions, phone calls, and home exercises.…
Phase: NA • Sponsor: UniDistance Suisse • Aim: Symptom relief
Last updated Jun 27, 2026 12:33 UTC
-
New therapy aims to curb opioid misuse in cancer patients
Symptom relief CompletedThis study tested a 6-session therapy called Acceptance and Commitment Therapy (ACT) for cancer patients at risk of opioid misuse. 40 adults with cancer and a high score on an opioid risk tool participated. The goal was to see if the therapy was feasible and acceptable, not yet t…
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Symptom relief
Last updated Jun 27, 2026 12:33 UTC
-
Writing away worries: new study helps young cancer survivors cope with body image
Symptom relief CompletedThis study tested whether a simple at-home writing program could help teens and young adults (ages 15-39) who finished cancer treatment feel less distressed about their body image and reduce anxiety. Thirty survivors participated in a four-week expressive writing program. The goa…
Phase: NA • Sponsor: University of Michigan Rogel Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
Coloring away chemo sickness: mandala therapy shows promise
Symptom relief CompletedThis study tested whether coloring mandala patterns can reduce nausea, vomiting, and fatigue, and improve psychological well-being in cancer patients receiving chemotherapy. 85 patients were split into a coloring group and a control group. The coloring session lasted 20-30 minute…
Phase: NA • Sponsor: University of Gaziantep • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
New pain coping program helps advanced cancer patients regain daily life
Symptom relief CompletedThis study tested a special pain coping skills program for people with advanced solid tumor cancer who have pain that interferes with daily activities. 211 patients were randomly assigned to either the program or standard care. The program taught ways to manage pain and find mean…
Phase: NA • Sponsor: Duke University • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
Can an online wellness program ease anxiety in chronic disease?
Symptom relief CompletedThis study tested a 12-week online mind-body program for adults with chronic conditions like heart failure, cancer, and liver disease. The program included mindful movement, meditation, breathwork, and coping skills. Researchers measured changes in anxiety, depression, fatigue, a…
Phase: NA • Sponsor: University of Alberta • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
Green tea extract tested as a frailty fighter for older cancer survivors
Symptom relief CompletedThis pilot study tested whether taking a green tea extract (EGCG) plus vitamin C daily for 12 weeks is safe and feasible for older cancer survivors who are frail or pre-frail. The study enrolled 24 people aged 65 and older who had completed cancer treatment. The main goal was to …
Phase: PHASE2 • Sponsor: University of Rochester • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
New stent technique may replace ileostomy for rectal cancer patients
Symptom relief CompletedThis study tested whether a temporary stent placed inside the bowel could replace a traditional ileostomy (a bag outside the body) after rectal cancer surgery. 570 patients at high risk for leaks were randomly assigned to either the stent or ileostomy. The goal was to see if the …
Phase: NA • Sponsor: Sir Run Run Shaw Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
3D models may speed up kidney surgery
Symptom relief CompletedThis study tested whether using a 3D model of a patient's kidney before surgery could shorten the time needed for robotic-assisted partial nephrectomy (removing a kidney tumor). 370 adults with small kidney tumors took part. The goal was to see if better planning with 3D imaging …
Phase: NA • Sponsor: University of Leipzig • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
Eating smart during cancer: study tests nutrition lessons
Symptom relief CompletedThis study looked at whether a structured nutrition education program can improve how much and how well cancer patients eat. 80 adults on active cancer treatment were split into two groups: one received personalized nutrition advice, the other did not. Researchers measured their …
Phase: NA • Sponsor: Istanbul Aydın University • Aim: Symptom relief
Last updated Jun 27, 2026 12:28 UTC
-
VR headsets may calm chemo patients
Symptom relief CompletedThis study tested whether using a virtual reality headset during chemotherapy can reduce distress, anxiety, and pain. 68 cancer patients were randomly assigned to either use VR for 15–30 minutes or receive standard care. Researchers measured changes in distress and pain scores be…
Phase: NA • Sponsor: Case Comprehensive Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:25 UTC
-
App helps kids with cancer report symptoms to doctors
Symptom relief CompletedThis study tested a mobile app called SyMon-SAYS that lets children with cancer report their symptoms weekly to their doctors. The goal was to see if using the app helps manage symptoms and improve quality of life. 216 children and their parents took part, with some using the app…
Phase: NA • Sponsor: Northwestern University • Aim: Symptom relief
Last updated Jun 27, 2026 12:24 UTC
-
Can a Stress-Management program help young cancer patients cope?
Symptom relief CompletedThis study tested whether a program called PRISM (Promoting Resilience in Stress Management) could help young adults aged 18-39 who have cancer or desmoid tumors manage anxiety and depression. The program teaches skills like stress management, goal setting, and positive thinking.…
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
New pill may ease severe cancer pain
Symptom relief CompletedThis study tested an experimental oral drug called Trichomylin® in 11 adults with advanced cancer who had moderate to severe pain despite taking strong opioids. The goal was to see if the drug is safe and can provide additional pain relief. Participants took the drug twice daily,…
Phase: PHASE2 • Sponsor: ZYUS Life Sciences Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Thyroid cancer patients may spend less time in discomfort with simple phone calls
Symptom relief CompletedThis completed phase 3 trial tested whether a patient outreach program—regular phone calls every two weeks—could help people with advanced medullary thyroid cancer spend less time experiencing moderate-to-severe side effects from the drug vandetanib. The study enrolled 205 adults…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Symptom relief
Last updated Jun 27, 2026 12:09 UTC
-
Smartwatches and exercise advice offer new hope for cancer fatigue
Symptom relief CompletedThis study tested a system that helps cancer patients manage fatigue. Patients used a phone app to report their tiredness and wore a smartwatch to track activity. Based on their fatigue level, they received personalized exercise advice. The goal was to see if this approach could …
Phase: NA • Sponsor: Taipei Medical University • Aim: Symptom relief
Last updated Jun 27, 2026 12:07 UTC
-
Spray freezing offers quick swallow relief for esophageal cancer patients
Symptom relief CompletedThis pilot study tested whether spray cryotherapy (freezing the tumor from inside the esophagus) can quickly improve swallowing in 15 patients with advanced esophageal cancer who were about to start chemotherapy and radiation. The goal was to ease difficulty swallowing sooner tha…
Phase: NA • Sponsor: Hunter Holmes Mcguire Veteran Affairs Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:07 UTC
-
Light strokes, big relief? touch therapy eases cancer fatigue
Symptom relief CompletedThis study tested whether a gentle, light-touch therapy (therapeutic touch) could help advanced cancer patients in palliative care sleep better and feel less tired. Sixty-one patients were randomly assigned to receive either 5 days of 10-15 minute touch sessions or standard care.…
Phase: NA • Sponsor: Erzurum Technical University • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
Can a Zoom-Based resilience program ease caregiver stress?
Symptom relief CompletedThis study tested a 9-session virtual mind-body program (SMART-3RP) to see if it helps caregivers of cancer survivors feel less stressed and more resilient. It compared the program to a standard online support group. The trial enrolled 94 participants and focused on whether the p…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
PET-CT scans could sharpen radiation targeting for liver tumors
Knowledge-focused CompletedThis study investigates whether PET-CT scans can accurately measure the radiation dose delivered by radioactive spheres during a liver cancer treatment called radioembolization. Researchers will compare scans taken before and after the procedure in patients with liver tumors. The…
Phase: NA • Sponsor: Fox Chase Cancer Center • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Family secrets? study maps how relatives talk about genetic health risks
Knowledge-focused CompletedThis study explored how family members share health information about genetic diseases like sickle cell, diabetes, and cancer. Over 1,000 adults completed surveys or interviews about their family health history and support. The goal was to understand social and relational factors…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Decade-Long study aims to unlock liver disease risks in HIV-Hepatitis b patients
Knowledge-focused CompletedThis study follows adults in Zambia who have both HIV and chronic hepatitis B to track liver health over up to 10 years. Researchers aim to understand how current HIV treatments affect hepatitis B and liver damage, and to identify factors that lead to serious outcomes like liver …
Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Scientists investigate why adrenal tumors produce hormones
Knowledge-focused CompletedThis study looked at adrenal gland tumors to understand why they form, why some release extra hormones, and why some are cancerous. Researchers studied 690 people with known or suspected adrenal tumors. Participants underwent tests like blood draws, imaging scans, and urine colle…
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Cooking up health: new study tests if free produce and lessons help cancer survivors
Knowledge-focused CompletedThis study looks at whether a 12-week program of cooking demonstrations, recipe cards, and free fruit and vegetable bundles can help cancer survivors eat healthier. Only 11 people are taking part, and the main goal is to see if such a program is practical and keeps people interes…
Phase: NA • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Hidden thyroid cancers: how common are they in patients with thyroiditis?
Knowledge-focused CompletedThis completed study from Minia University looked at 200 patients with autoimmune thyroiditis (an inflamed thyroid) who had thyroid surgery. The goal was to see how often thyroid cancer is found by accident when examining the removed tissue. Researchers checked for cancer in pati…
Phase: NA • Sponsor: Minia University • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Hidden danger: study probes blood clot risk in cancer patients with COVID-19
Knowledge-focused CompletedThis study investigates how often cancer patients with COVID-19 develop dangerous blood clots (venous thromboembolism). Researchers will screen participants using ultrasound and blood tests to detect clots, whether or not they cause symptoms. The goal is to understand the true ra…
Phase: NA • Sponsor: Centre Antoine Lacassagne • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
New document helps young adults voice End-of-Life wishes
Knowledge-focused CompletedThis study tested a document called Voicing My CHOiCES, designed to help young adults (ages 18-39) with serious illnesses like cancer or HIV discuss their care preferences. Participants filled out questionnaires about anxiety, social support, and communication, then reviewed the …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Blood test could reveal how lung cancer evolves during treatment
Knowledge-focused CompletedThis study investigates whether a simple blood test (liquid biopsy) can track how advanced non-small cell lung cancer changes during immunotherapy or targeted therapy. Researchers will analyze tumor DNA circulating in the blood to see if it can predict treatment response and dete…
Sponsor: Geneplus-Beijing Co. Ltd. • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
10,000 cancer records analyzed to supercharge future treatments
Knowledge-focused CompletedThis study collects and analyzes health records from 10,000 cancer patients across multiple sites. Researchers will use this real-world data to better understand patient populations, improve clinical trial design, and support drug development. No new treatments are tested—the goa…
Sponsor: Tempus AI • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
40,000 patients studied: does a simpler cancer drug dose work just as well?
Knowledge-focused CompletedThis completed study looked at 40,000 people with metastatic cancer who received the drug nivolumab. Researchers compared the old way of dosing (based on body weight) with a newer, simpler fixed dose. They used national health data to see if the fixed dose was just as good and mo…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Empty bladder may steady the target in rectal cancer radiation
Knowledge-focused CompletedThis study investigates whether having an empty bladder reduces movement of the mesorectum (tissue around the rectum) during radiotherapy for rectal cancer. About 50 adults with rectal cancer receive planning CT scans and weekly CBCT scans under both empty and full bladder condit…
Phase: NA • Sponsor: Institut Cancerologie de l'Ouest • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
New app aims to help cancer patients report side effects from home
Knowledge-focused CompletedThis study tested whether a smartphone app called QuestOnco can reliably track side effects in 134 adult cancer patients receiving active treatment. Patients used the app to report symptoms, and researchers compared those reports to standard paper questionnaires. The goal was to …
Phase: NA • Sponsor: Centre Hospitalier Régional Metz-Thionville • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Real-Time tissue test may help surgeons avoid unnecessary neck dissections in thyroid cancer
Knowledge-focused CompletedThis pilot study tested whether a rapid lab test called frozen section analysis, done during thyroid surgery, can help surgeons decide how many lymph nodes to remove from the neck. The study included 66 adults with low-risk thyroid cancer and no signs of spread before surgery. Th…
Sponsor: Eleonora Lori, MD • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Does anesthesia choice impact liver cancer recurrence?
Knowledge-focused CompletedThis study looked at 153 people having liver cancer surgery to see if the type of anesthesia they received affected their recovery and immune response. Researchers compared different anesthesia methods and measured blood markers related to inflammation and immune cell activity. P…
Phase: NA • Sponsor: Iuliu Hatieganu University of Medicine and Pharmacy • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Lab study tests antibody that could unlock immune attack on liver cancer
Knowledge-focused CompletedThis completed study looked at a new antibody called anti-SIRPα as a potential immunotherapy for liver cancer. Researchers used blood and tissue samples from 30 liver cancer patients to see how the antibody affects immune cells. The goal was to understand whether blocking the SIR…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Your tongue could reveal cancer: AI study analyzes 4,100 people
Knowledge-focused CompletedThis completed study collected tongue images and clinical data from 4,100 people—both cancer patients and healthy individuals—to build a database. Researchers plan to use artificial intelligence to analyze tongue features for early cancer screening and diagnosis. The study did no…
Sponsor: Zhejiang Cancer Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
New radiation approach targets multiple tumors at once in early trial
Knowledge-focused CompletedThis early-phase trial tested a precise, high-dose radiation technique called stereotactic body radiotherapy (SBRT) in 42 patients with breast, lung, or prostate cancer that had spread to several places in the body. The main goal was to find the safest dose and check for side eff…
Phase: PHASE1 • Sponsor: NRG Oncology • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Gene test could predict kidney cancer in transplant patients
Knowledge-focused CompletedThis completed study examined whether a specific variation in the VEGF gene (rs699947) is linked to a higher risk of developing kidney cancer in people who have received a kidney transplant. Researchers analyzed DNA from 272 transplant patients, some of whom had kidney cancer. Th…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Study aims to cut hospital time after liver surgery by looking beyond medicine
Knowledge-focused CompletedThis completed study looked at 3000 patients having liver surgery to see if considering both medical and social factors could reduce how long they stay in the hospital. Researchers tracked things like complications and readmissions. The goal is to find ways to improve recovery an…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
New tool may predict kidney cancer drug success
Knowledge-focused CompletedThis study tested a prediction tool (nomogram) to see if it could forecast how patients with metastatic clear cell renal cell carcinoma respond to the targeted therapy sunitinib. Researchers looked at 45 patients who had their kidney removed and were treated with sunitinib as the…
Sponsor: Rennes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Can a Child's cancer be inherited? new study digs into family DNA
Knowledge-focused CompletedThis study looks at the DNA of 100 children (and young adults up to age 17) who have cancer, along with the DNA of their healthy parents. The goal is to find genetic changes that may have caused the cancer. By comparing the child's DNA to both parents', researchers hope to discov…
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Heart MRI may reveal hidden damage in young cancer survivors after sepsis
Knowledge-focused CompletedThis pilot study tested whether a heart MRI could be done safely and effectively in children with cancer who recently had sepsis. The goal was to see if the MRI could find hidden heart inflammation or weakness that standard tests might miss. Only 7 children took part, and the foc…
Phase: NA • Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Scientists hunt for proteins that predict breast cancer spread
Knowledge-focused CompletedThis completed study analyzed tissue samples from 108 breast cancer patients to identify proteins linked to early cancer invasion. The goal was to find markers that could help assess the risk of tumor spread in patients without lymph node involvement. Researchers focused on listi…
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Could stomach surgery raise cancer risk? new study investigates
Knowledge-focused CompletedThis study looked at 100 patients who had sleeve gastrectomy for severe obesity. Researchers checked how many developed Barrett's esophagus, a condition that can lead to esophageal cancer, five or more years after surgery. They also examined whether routine endoscopy (a camera te…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
PET scan patients may soon be allowed to move freely during the long wait
Knowledge-focused CompletedThis study tested whether letting patients move freely between the injection of a radioactive tracer and the PET scan affects image quality. Normally, patients must rest for an hour to avoid muscle uptake that can blur results. The trial involved 284 adults with cancer or needing…
Phase: NA • Sponsor: Centre Hospitalier Régional d'Orléans • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Texts and nudges may help more people get cancer genetic testing
Knowledge-focused CompletedThis study tested three types of messages to encourage genetic testing in 1,283 people at risk for hereditary breast and ovarian cancer. Participants received an electronic health record message, then a text message, then a doctor's reminder if needed. The goal was to see which a…
Phase: NA • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Scientists probe Gut-Liver link in alcohol and fatty liver cancers
Knowledge-focused CompletedThis study looked at 180 people with liver cancer (hepatocellular carcinoma) who also had cirrhosis caused by either fatty liver disease or alcohol use. Researchers compared immune cells and gut bacteria in the liver to understand why cancer develops. The goal was to gather knowl…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can a quick GP visit improve cancer care? new study aims to find out
Knowledge-focused CompletedThis study looks at whether it's possible for people diagnosed with solid tumors to have a follow-up visit with their general practitioner within 15 days of learning their diagnosis. Researchers will track how many patients actually attend this visit and why some might not. The g…
Phase: NA • Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can a short video boost genetic know-how in pediatric cancer families?
Knowledge-focused CompletedThis study looked at whether an informational video could help parents and teens better understand genetic testing after a new cancer diagnosis. About 355 families from a children's hospital took part. The goal was to see if the video was acceptable and improved knowledge about g…
Phase: NA • Sponsor: Children's Hospital of Philadelphia • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New registry aims to unlock secrets of rare kidney cancer
Knowledge-focused CompletedThis completed study created a registry of 28 patients with TFE renal cell carcinoma, a rare kidney cancer. Researchers collected medical data, tumor samples, and images to better understand the disease. The goal is to use this information to guide future research and develop mor…
Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Large study reveals Real-World outcomes of immunotherapy in advanced kidney cancer
Knowledge-focused CompletedThis study reviewed medical records of 494 adults with advanced kidney cancer who received immunotherapy as their first treatment. Researchers looked at how long patients stayed on treatment, how they responded, and survival rates. The goal was to understand which treatment combi…
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Study aims to unlock secrets of immunotherapy skin reactions
Knowledge-focused CompletedThis study observed 255 cancer patients receiving immunotherapy to understand why some develop skin side effects. Researchers measured immune markers and lipids in the skin and blood. The goal is to identify patterns that could predict or explain these reactions.
Sponsor: National Jewish Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Kidney cancer patients in Real-World clinics get immunotherapy: does it work?
Knowledge-focused CompletedThis study followed 623 adults in France with advanced kidney cancer who were starting treatment with the immunotherapy drugs nivolumab (with or without ipilimumab) for the first time. Unlike a clinical trial, this was an observational study that simply tracked what happened in e…
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can a tailored diet help cancer survivors? new study tests the recipe
Knowledge-focused CompletedThis study tested a nutrition program for cancer survivors who are overweight or have obesity. The program included one-on-one counseling with a dietitian, behavioral skills training, and group support. The goal was to see if the program was easy to run and acceptable to particip…
Phase: NA • Sponsor: University of Colorado, Denver • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Zambia study tracks hepatitis b outcomes in hundreds of patients
Knowledge-focused CompletedThis study followed 326 adults in Zambia with chronic hepatitis B for up to 5 years. Researchers tracked how the virus behaves, how many patients need treatment, and how many develop serious liver problems like cirrhosis or liver cancer. The goal was to better understand the dise…
Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Can bone markers predict survival in lung cancer patients?
Knowledge-focused CompletedThis study enrolled 200 adults with lung adenocarcinoma that has spread to the bones. Researchers took bone biopsies, scans, and blood tests to measure bone and metabolic markers. The goal is to see if these markers are linked to how long patients live. This is an observational s…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Cancer drug opdivo qvantig under the microscope: who gets it and how?
Knowledge-focused CompletedThis completed study reviewed medical records of 200 adults with cancer who received the drug nivolumab (Opdivo) either as an intravenous infusion or as a subcutaneous injection (Opdivo Qvantig) in community oncology clinics across the United States. The goal was to describe the …
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Study reveals why immunotherapy works differently in liver, lung, and brain tumors
Knowledge-focused CompletedThis study looked at medical records of 938 adults with solid tumors who received immunotherapy. Researchers compared how well the treatment worked when cancer had spread to different organs like the liver, brain, lung, or bone. The goal is to understand why some metastatic sites…
Sponsor: Wenlong Zhong, MD • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Can cancer patients recover at home with remote monitoring?
Knowledge-focused CompletedThis study tested a program that lets recently hospitalized cancer patients recover at home with remote monitoring of symptoms, vital signs, and weight. The program includes home visits and close communication with the oncology team. Researchers wanted to see if this approach is …
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Proton therapy gets a daily Tune-Up in small pilot study
Knowledge-focused CompletedThis pilot study tested whether it's possible to adjust proton radiation plans each day while the patient is on the treatment table. Ten adults with solid tumors took part. The goal was to see if this approach is safe and practical enough to study in a larger trial.
Phase: NA • Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
New study checks drug safety for prostate cancer patients
Knowledge-focused CompletedThis study looked at how an experimental drug called SHR3680 affects the way the body processes three other common drugs: digoxin, rosuvastatin, and metformin. Thirty-six men with prostate cancer took SHR3680 along with these drugs to see if there were any interactions. The goal …
Phase: PHASE1 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
Small study tests best way to mix chemo for liver tumors
Knowledge-focused CompletedThis study looked at 10 people with liver cancer (HCC) who were getting a standard treatment called chemoembolization (c-TACE). The goal was to see if mixing the chemotherapy drug doxorubicin with salt water or a contrast dye changes how the drug spreads inside the tumor. Researc…
Phase: PHASE4 • Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
Instacart and nutrition calls may ease food insecurity for cancer survivors
Knowledge-focused CompletedThis study tested whether providing grocery delivery (via Instacart) and weekly nutrition coaching calls helps cancer survivors who struggle to afford healthy food. Forty survivors who had finished active cancer treatment took part. The goal was to see if this support was practic…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Cancer Patients' blood thinner mystery solved?
Knowledge-focused CompletedThis study measured how two common blood thinners (rivaroxaban and apixaban) behave in 193 adults with active cancer who also had blood clots or atrial fibrillation. Researchers aimed to understand factors like age, weight, and kidney function that affect drug levels. The goal wa…
Sponsor: Groupe Hospitalier Pitie-Salpetriere • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Cancer Patients' own needs may guide better care, study finds
Knowledge-focused CompletedThis completed study at Sohag Oncology Center tested whether a quality-of-life survey could help match cancer patients' needs with the right supportive care, like pain management or nutrition counseling. Over 4,400 adult cancer patients completed the EORTC QLQ-C30 questionnaire, …
Sponsor: Sohag Oncology Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Glow-in-the-Dark antibody could help surgeons spot prostate cancer
Knowledge-focused CompletedThis early-phase trial tested a fluorescent antibody that attaches to prostate cancer cells. Seven men with moderate- to high-risk prostate cancer received the antibody before robotic prostate removal surgery. The goal was to see if the glowing antibody could help surgeons identi…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
AI learns to spot cancer pain from faces and voices
Knowledge-focused CompletedThis study tested whether machine learning can detect cancer pain by analyzing facial expressions, voice, and speech. 83 people with cancer recorded videos at clinic visits and at home over 3 months. The goal was to see if this technology could classify pain levels in a diverse g…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Massive study digs into genetic roots of stomach cancer
Knowledge-focused CompletedThis study collected information from 733 people with a personal or family history of hereditary stomach cancer. The goal was to better understand how these cancers develop and what genes are involved. Participants provided medical history, blood samples, and genetic testing. The…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Heart monitor reveals hidden damage from cancer radiation
Knowledge-focused CompletedThis study looked at 24 people with lung or esophageal cancer who received radiation or chemo-radiation near the heart. Participants wore a small heart monitor to catch any heart changes that might otherwise go unnoticed. The goal was to see how often heart problems occur after s…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
New breast cancer locator aims to reduce repeat surgeries
Knowledge-focused CompletedThis study tested a custom-made device called the Breast Cancer Locator (BCL) in 35 women with non-palpable breast cancer. The device helps surgeons see exactly where the tumor is during breast-conserving surgery, with the goal of removing all cancer in one go and reducing the ne…
Phase: NA • Sponsor: CairnSurgical, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
Massive cancer registry tracks genetic Testing's Real-World impact
Knowledge-focused CompletedThis completed registry followed nearly 8,000 adults with solid tumors who had next-generation sequencing (NGS) genetic testing. The goal was to collect real-world data linking test results, treatments, and survival. No new drug or intervention was tested; instead, the registry a…
Sponsor: Hoffmann-La Roche • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Gastric cancer surgery: new index could level the playing field for hospitals
Knowledge-focused CompletedThis study created a new tool called the SAH Index to fairly evaluate how well hospitals and surgeons perform gastric cancer surgery. Gastric cancer is serious and often requires major surgery, but comparing results is tricky because patients have different health risks. The rese…
Sponsor: Ruijin Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
New online tool aims to pick the right patients for cancer drug trials
Knowledge-focused CompletedResearchers tested a new online tool called PIPO that helps doctors estimate how long a cancer patient might live. This information can guide decisions about which patients to enroll in early-phase clinical trials. The study included 586 people who had already joined phase 1 or p…
Sponsor: Vall d'Hebron Institute of Oncology • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
AI model aims to predict cancer Patients' emergency room visits
Knowledge-focused CompletedThis study tested a machine learning model that uses electronic health records to predict which cancer patients receiving infusion therapy are at risk of needing emergency care or hospitalization within 30 days. Researchers analyzed data from over 4,700 patients at UCSF. The goal…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
VR headsets calm cancer patients before radiation
Knowledge-focused CompletedThis study looked at whether a virtual reality (VR) education program could help first-time radiation therapy patients understand their treatment better and reduce anxiety and depression. 84 cancer patients were split into two groups: one received VR education, the other standard…
Phase: NA • Sponsor: Asia University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Kidney cancer study reveals muscle loss clues in 161 patients
Knowledge-focused CompletedThis study looked at how lifestyle factors like obesity and muscle loss affect kidney cancer risk and survival after kidney removal. Researchers collected blood, tissue, and questionnaire data from 161 patients over up to 5 years. The goal was to understand how to personalize tre…
Sponsor: University of Utah • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
8,000 kidney tumor samples collected to unlock cancer clues
Knowledge-focused CompletedThis completed research study collected and stored tumor tissue, blood, and urine samples from 8,000 children and young adults with kidney tumors. The goal was to help scientists study DNA changes and find biomarkers that could improve understanding of these cancers. No treatment…
Sponsor: Children's Oncology Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
New program aims to break down barriers to cancer trial participation
Knowledge-focused CompletedThis pilot study tested a program called GUIDE, which uses a trained navigator to help cancer patients overcome social and financial barriers to joining clinical trials. The study included 100 adults with cancer who were eligible for a trial and had at least one health-related so…
Phase: NA • Sponsor: Fred Hutchinson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
New website aims to close cancer care gap for black patients
Knowledge-focused CompletedThis study created and tested an educational website to help Black and African American cancer patients learn about personalized cancer treatments and clinical trials. Researchers interviewed 48 patients and caregivers, then tested the website with 33 patients. The goal was to se…
Phase: NA • Sponsor: Rutgers, The State University of New Jersey • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
AI takes on cancer experts: who wins?
Knowledge-focused CompletedThis study looked at whether an AI computer program could suggest cancer treatments that match what experts recommend. Researchers reviewed medical records of 30 people with stomach, colon, or pancreatic cancer. They entered key details into the AI and compared its suggestions to…
Sponsor: Medizinische Hochschule Brandenburg Theodor Fontane • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Thousands tracked in Largest-Ever liver cancer bead therapy registry
Knowledge-focused CompletedThis registry followed over 1,000 liver cancer patients who received SIR-Spheres—tiny radioactive beads injected into the liver's blood supply to kill tumors. The goal was to see how this treatment is used in real hospitals and how it affects survival, side effects, and quality o…
Sponsor: Cardiovascular and Interventional Radiological Society of Europe • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Study tests whether nudges on social media can stop cancer myths in their tracks
Knowledge-focused CompletedThis completed study looked at whether adding a warning prompt above cancer misinformation posts on social media encourages people to flag them. Researchers recruited 294 US adults who had either been diagnosed with cancer or cared for someone with cancer. Participants saw fake s…
Phase: NA • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
New model could spare prostate cancer patients unnecessary surgery
Knowledge-focused CompletedThis study aimed to improve how doctors predict whether prostate cancer has spread to nearby lymph nodes. Researchers combined patient information, MRI scans, and genetic data from 367 men who had their prostate removed. The goal was to create a more accurate tool to help decide …
Sponsor: Francesco Montorsi • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Massive study sheds light on esophageal cancer surgery outcomes
Knowledge-focused CompletedThis study analyzed data from nearly 3,000 patients who had surgery for esophageal cancer between 2000 and 2010. Researchers looked at factors like patient health, treatment approach, and surgical technique to see what influences cancer recurrence and survival. The goal is to bet…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
New ultrasound technique aims to better measure liver health
Knowledge-focused CompletedThis study tested a new ultrasound technique called ARFI to measure liver stiffness in 109 people, including healthy volunteers and patients with liver conditions. The goal was to understand normal stiffness values and how they change with disease or treatment. This is an observa…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Tiny gold seeds could sharpen radiation for spine tumors
Knowledge-focused CompletedThis study tested whether implanting tiny gold markers near spinal tumors helps deliver radiation more accurately. Researchers also checked if giving slightly more radiation to the nearby esophagus is safe, which might improve tumor control. The study involved 41 adults with vari…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Standing ultrasound spots hidden liver tumors better than lying down
Knowledge-focused CompletedThis study tested whether having patients stand during an ultrasound helps doctors see small liver tumors near the diaphragm that are often missed when lying down. Researchers scanned 95 people with confirmed liver lesions in three positions: standing, lying on their back, and ly…
Sponsor: The First Hospital of Jilin University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
New scan spots chemo damage to heart and muscles early
Knowledge-focused CompletedThis study tested whether a special MRI scan (31P-MRS) can detect early signs of damage to heart and muscle cells caused by chemotherapy drugs like doxorubicin. Twelve cancer patients scheduled for chemo underwent three scans over time. The goal was to see if the scan could measu…
Sponsor: UMC Utrecht • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Can an app help kidney cancer patients manage treatment side effects?
Knowledge-focused CompletedThis study looked at whether a software program called Carevive could help patients with advanced kidney cancer track side effects from their oral targeted therapy or immunotherapy. 21 patients used the software to report symptoms and received self-care tips. The goal was to see …
Phase: NA • Sponsor: University of Rochester • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
New scanner aims to sharpen cancer radiation targeting
Knowledge-focused CompletedThis study tested a new on-couch imaging system called HyperSight, which takes 3D X-ray pictures (CBCT) of cancer patients right before their radiation treatment. 46 adults with head/neck, chest, abdomen, or pelvic cancers received both the new HyperSight scan and a standard scan…
Phase: NA • Sponsor: Varian, a Siemens Healthineers Company • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
New nutrition training boosts oncology Nurses' skills in vietnam
Knowledge-focused CompletedThis study tested a co-designed nutritional training program for 20 oncology nurses in Vietnam. The program included a three-day workshop with theory and hands-on practice, focusing on managing diet-related side effects of cancer treatment like nausea and diarrhea. Researchers me…
Phase: NA • Sponsor: VinUniversity • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
AI vs. jargon: can robots make cancer info easier to read?
Knowledge-focused CompletedThis study tested whether an AI tool can help health providers write medical summaries that are easier for patients to understand. 120 providers were split into two groups: one used the AI tool, the other did not. The goal was to see if AI could improve readability and save time,…
Phase: PHASE2 • Sponsor: University of Southern California • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
New classification system may help guide treatment for colorectal cancer spread to liver
Knowledge-focused CompletedThis study tested a new classification system for people whose colorectal cancer has spread only to the liver. Researchers looked at survival rates and compared different patient groups to see if the system helps predict outcomes. The goal is to better identify which patients mig…
Sponsor: University Hospital, Linkoeping • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
AI model may personalize liver cancer care after surgery
Knowledge-focused CompletedThis study analyzed data from 1005 liver cancer patients to see who benefits from a treatment called TACE after surgery. Using machine learning, researchers aimed to predict individual patient outcomes. The goal is to help doctors decide whether to recommend TACE or just monitor …
Sponsor: Anhui Provincial Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
New study tests simple ways to track muscle loss in kids with cancer
Knowledge-focused CompletedThis study looked at whether it's possible to measure muscle mass and physical function in children (ages 8-21) with newly diagnosed solid tumors or lymphoma during cancer treatment. Researchers used simple tests like a 6-minute walk and a special drink to measure muscle, along w…
Phase: NA • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Cancer surgery recovery: quality of life under the microscope
Knowledge-focused CompletedThis study tracked 295 adults who had high-risk surgery for stomach, esophagus, pancreas, or liver cancer. Researchers measured quality of life before surgery and again at 6 and 12 months after. They also asked patients and their family members if they regretted the decision to h…
Sponsor: University Hospital, Geneva • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Can the mediterranean diet survive chemo? new study investigates
Knowledge-focused CompletedThis study looked at how cancer treatment changes patients' ability to stick with a Mediterranean diet. Researchers followed 116 patients starting chemotherapy or immunotherapy, checking their diet adherence and sensory changes (taste and smell) at the start and after 9 weeks. Th…
Phase: NA • Sponsor: Centre Antoine Lacassagne • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:26 UTC
-
AI in cancer care: 7,151 people share their hopes and fears
Knowledge-focused CompletedThis study looked at how cancer patients, the general public, and healthcare professionals use and feel about large language models (like ChatGPT) for making cancer treatment decisions. Over 7,000 people from 30 countries completed a survey. The goal was to understand current usa…
Sponsor: Technical University of Munich • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:26 UTC
-
Fiber-Fed mice show promise against prostate cancer
Knowledge-focused CompletedThis completed study from the University of Aberdeen looked at how dietary fiber supplements might influence prostate cancer. Researchers gave mice different fibers (inulin, pectin, hemp hull) along with stool samples from healthy men over 60. They then measured changes in gut ba…
Sponsor: University of Aberdeen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:26 UTC
-
Can better Doctor-Patient bonds reduce cancer care disparities?
Knowledge-focused CompletedThis study looked at how trust and communication (called a therapeutic alliance) between Latino/a advanced cancer patients and their oncologists might affect care. Researchers interviewed 4 doctors and held focus groups with 10 patients to understand barriers and what helps build…
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:26 UTC
-
Silent threat: low albumin levels linked to worse outcomes in elderly cancer surgery
Knowledge-focused CompletedThis study looked at 330 older adults (65+) who had cancer surgery to see if low albumin levels before surgery led to more complications. Researchers compared patients with low albumin to those with normal levels, tracking problems like infections, hospital stay length, and ICU n…
Sponsor: Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:26 UTC
-
New risk score may predict breathing complications after cancer surgery
Knowledge-focused CompletedThis study tested whether a tool called the ARISCAT score can predict lung complications (like pneumonia or collapsed lung) after major abdominal cancer surgery. Researchers followed 410 adults who had surgery under general anesthesia. The goal was to see if the score could help …
Sponsor: Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:26 UTC
-
Cancer patients help design better quality-of-life surveys
Knowledge-focused CompletedThis study aimed to improve how we measure quality of life in cancer patients whose disease is progressing. Researchers interviewed 20 patients, their carers, and healthcare professionals to learn their preferences on how often and in what way to collect this information. The goa…
Sponsor: University of Leeds • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
Hepatitis & liver cancer risk explored in immigrant communities
Knowledge-focused CompletedThis study tested 892 African and Asian immigrants for hepatitis B and C to understand how these infections raise the risk of liver cancer. Researchers also checked vaccination rates and tracked new cancer cases over time. No treatment was given; the goal was to gather informatio…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Cancer Patients' work struggles revealed in new study
Knowledge-focused CompletedThis study looked at how cancer patients feel about returning to work while undergoing treatment. Researchers interviewed 20 patients to understand their needs and how work affects their sense of normalcy. The goal is to help nurses provide better support for work-related challen…
Sponsor: Centro di Riferimento Oncologico - Aviano • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Tumor DNA test may match patients to smarter cancer drugs
Knowledge-focused CompletedThis study looked at whether analyzing the DNA of a patient's tumor can help doctors pick a targeted therapy for advanced or metastatic cancer. Researchers enrolled 550 adults with various solid tumors that had spread. They took biopsy or blood samples to search for genetic chang…
Phase: NA • Sponsor: Institut Paoli-Calmettes • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Scientists hunt for biomarkers in pancreatic cancer to guide therapy
Knowledge-focused CompletedThis study aimed to find biological markers (biomarkers) in pancreatic tumor cells and blood that could help predict how well a patient might respond to treatment. Researchers analyzed genetic and protein information from tumor samples collected via ultrasound-guided biopsy, as w…
Phase: NA • Sponsor: Institut Paoli-Calmettes • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Ultrasound vs. MRI: which is better for catching liver cancer early?
Knowledge-focused CompletedThis study looked at 211 people with liver cirrhosis to see which screening method works better for detecting liver cancer: an ultrasound every 6 months or an MRI once a year. Participants received both tests, and researchers measured how often each test correctly found cancer. T…
Sponsor: JOON-IL CHOI • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Study reveals hidden burdens of cancer caregivers
Knowledge-focused CompletedThis study looked at the needs and challenges of family caregivers who help older adults (70+) with cancer. Researchers interviewed 78 caregivers to understand their social and personal situations, and tested a personalized support program with phone follow-ups. The goal was to s…
Phase: NA • Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Scientists hunt for clues to why immunotherapy fails in most patients
Knowledge-focused CompletedThis study looked at 135 people with advanced lung cancer, lymphoma, or other tumors treated with immunotherapy drugs called checkpoint inhibitors. Researchers collected blood and tumor samples over time to measure immune cells and molecules that might predict whether the treatme…
Phase: NA • Sponsor: Institut Paoli-Calmettes • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
New drug tracking study offers no cure, but key insights for future cancer treatments
Knowledge-focused CompletedThis study looked at how the drug tuvusertib is absorbed, broken down, and removed from the body in 12 people with advanced solid tumors. Participants received a tiny radioactive tracer to track the drug. The main goal was to understand the drug's path in the body, not to treat t…
Phase: PHASE1 • Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Radiation before knife: small study tests new pancreatic cancer approach
Knowledge-focused CompletedThis study looked at whether giving a short, strong dose of radiation right before surgery is possible for people with pancreatic cancer. Ten patients took part to see if the approach was safe and could help surgeons remove the tumor completely. The main goal was to check for com…
Phase: NA • Sponsor: CCTU- Cancer Theme • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:10 UTC
-
New study tracks COVID vaccine durability in chronic illness patients
Knowledge-focused CompletedThis completed study followed 360 adults and children with chronic respiratory and other medical conditions to see how their immune systems responded to COVID-19 vaccines over 18 months. Researchers measured antibody, T cell, and B cell levels before vaccination and every 3 month…
Sponsor: National Jewish Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:10 UTC
-
New endoscopic technique hunts cancer cells in the portal vein
Knowledge-focused CompletedThis study tested whether it is safe and possible to collect a blood sample from the portal vein (a major liver blood vessel) during a routine endoscopic ultrasound in 23 people with pancreatic cancer. The goal was to find and count circulating tumor cells (cancer cells in the bl…
Phase: NA • Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Can a simple RNA test predict pancreatic cancer outcomes?
Knowledge-focused CompletedThis study examined small RNA molecules called microRNAs in tissue samples from 57 people with pancreatic cancer. The samples were collected during a routine endoscopic ultrasound procedure. Researchers aimed to see if certain microRNA patterns are linked to how aggressive the ca…
Sponsor: Carol Davila University of Medicine and Pharmacy • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Which scanner spots the smallest tumors? new study puts two to the test
Knowledge-focused CompletedThis study tested two different PET-CT scanners to see which one is better at finding very small cancer spots (less than 1 cm) in patients. Twenty-four people with cancer each had two scans, one on each machine. The researchers then added virtual lesions to the images to compare …
Phase: NA • Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Immunotherapy side effects under the microscope: MOTIVATE study tracks 150 patients
Knowledge-focused CompletedThis study followed 150 people with solid tumors who were starting immunotherapy (immune checkpoint inhibitors) as part of their regular care. Researchers collected data on side effects and asked patients to fill out questionnaires before each treatment. The goal was to better un…
Phase: NA • Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Mukbang watching studied as appetite booster for young cancer patients
Knowledge-focused CompletedThis study looked at whether children with cancer who watch mukbang (eating shows) have better appetite during hospital treatment. Researchers tracked 179 children's eating habits and video watching over several days. The goal was to see if there's a link that could help improve …
Sponsor: Sun Yat-sen University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Blood markers may reveal chemo response in just weeks
Knowledge-focused CompletedThis study looked at 74 people with metastatic colorectal cancer starting their first chemotherapy. Researchers took blood samples early in treatment to measure three markers: CEA, circulating tumor DNA, and total cell-free DNA. The goal was to see if early changes in these marke…
Phase: NA • Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Scientists examine immune clues in ovarian cancer
Knowledge-focused CompletedThis completed study looked at tumor samples from 687 women with advanced high-grade serous ovarian cancer who were treated with chemotherapy. Researchers examined different types of immune cells in the tumors to see if they were linked to how well patients did. The goal was to b…
Sponsor: Hellenic Cooperative Oncology Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Routine BRCA testing for ovarian cancer patients proves feasible in irish study
Knowledge-focused CompletedThis study tested whether it is practical to routinely check ovarian cancer tumors for BRCA gene mutations in the clinic. Researchers enrolled 200 patients with high-grade serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer. They used blood and tumor samp…
Sponsor: Cancer Trials Ireland • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
New biomarker may predict which cancer drugs work best
Knowledge-focused CompletedThis completed study tested whether a new biomarker called 'mass response' can predict how well a cancer therapy will work. Researchers collected tumor cells from 72 patients with various cancers through fluid drainage or biopsies. The goal was to see if this biomarker could guid…
Sponsor: Travera Inc • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
500 patients studied to uncover why colorectal cancer survival varies by region
Knowledge-focused CompletedThis study looked back at the medical records of 500 people with colorectal cancer from two regions in China. Researchers collected information on patients' backgrounds, lifestyle, and treatments to find patterns that affect survival. The goal was to understand regional differenc…
Sponsor: Qianfoshan Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Study reveals best Surgery-Radiation combos for Better-Looking breasts after cancer
Knowledge-focused CompletedThis completed study involved 775 women who had breast-conserving surgery and radiation for breast cancer. Researchers compared different surgery and radiation techniques to see which ones led to less breast hardening (fibrosis) and better cosmetic results. The goal was to find w…
Sponsor: Erasmus Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Blood test could guide pancreatic cancer therapy
Knowledge-focused CompletedThis completed study looked at whether a simple blood test (liquid biopsy) can find genetic markers that predict how well pancreatic cancer treatments work. Researchers analyzed DNA from tumors circulating in the blood of 420 patients with pancreatic cancer. The goal was to disco…
Sponsor: National Cancer Center, Korea • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Heart risk alert: troponin test may protect cancer patients on immunotherapy
Knowledge-focused CompletedThis completed study looked at 300 cancer patients treated with immune checkpoint inhibitors to see if measuring troponin levels could help detect serious heart problems early. The goal was to prevent major cardiovascular events like heart attack or stroke without unnecessarily s…
Sponsor: Institut Mutualiste Montsouris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Cancer drug heart risk mystery probed in new study
Knowledge-focused CompletedThis study looked at how immune checkpoint inhibitors, a type of cancer drug, might affect blood vessels and increase heart risks. Researchers measured blood vessel function and checked for related markers in 39 cancer patients before and after starting treatment. The goal was to…
Phase: NA • Sponsor: Institut Mutualiste Montsouris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Could T-DXd outperform standard care for multiple HER2-Positive cancers? new study investigates
Knowledge-focused CompletedThis study looks at whether the drug T-DXd works better than standard treatments for people with several types of HER2-positive solid tumors. Researchers will compare data from previous T-DXd trials with real-world medical records of patients who received standard care. The goal …
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC